{"gene":"UBQLN2","run_date":"2026-06-10T10:51:56","timeline":{"discoveries":[{"year":2011,"finding":"UBQLN2 mutations impair ubiquitinated protein degradation. Functional analysis in patient-derived cells showed that ALS-linked UBQLN2 mutations lead to impairment of the protein degradation pathway, linking ubiquilin 2 abnormalities to defects in the ubiquitin-proteasome system and abnormal protein aggregation.","method":"Functional degradation assays in patient-derived cells","journal":"Nature","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional assay in patient cells, single lab, foundational study but limited mechanistic resolution in the abstract","pmids":["21857683"],"is_preprint":false},{"year":2013,"finding":"UBQLN2 interacts with UBXD8 (an ER membrane protein involved in ERAD substrate translocation) both in vitro and in vivo via co-IP and in vitro binding assays; ALS-linked pathogenic mutation impairs this interaction, disrupting ER-associated protein degradation and causing greater accumulation of ERAD substrates.","method":"Co-immunoprecipitation, in vitro binding assay, ERAD substrate accumulation assay","journal":"Journal of neurochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP plus in vitro binding plus functional ERAD assay, single lab","pmids":["24215460"],"is_preprint":false},{"year":2013,"finding":"UBQLN2 binds directly to the C-terminal region of TDP-43 with high affinity (KD ~6–9 nM), as demonstrated by binding assays and co-IP in H4 cells. Overexpression of UBQLN2 enhances clearance of TDP-43 and C-terminal TDP-43 fragments, reducing their steady-state levels.","method":"In vitro binding assay (KD determination), co-immunoprecipitation, cell overexpression with immunoblot","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 1–2 / Moderate — quantitative in vitro binding plus Co-IP plus cell-based functional assay, single lab","pmids":["23541532"],"is_preprint":false},{"year":2016,"finding":"UBQLN2 acts together with the HSP70-HSP110 disaggregase machinery to clear protein aggregates via the 26S proteasome, independent of autophagy. UBQLN2 recognizes client-bound HSP70 and links it to the proteasome. ALS-linked UBQLN2 mutations are defective in chaperone (HSP70) binding and impair aggregate clearance. This pathway is active in the nucleus where autophagy does not operate.","method":"In vitro reconstitution, co-immunoprecipitation, cellular aggregate clearance assays, mouse behavioral tests, nucleus-specific assays","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple orthogonal methods including in vitro reconstitution, Co-IP, functional cellular assays, and in vivo mouse models in a single rigorous study","pmids":["27477512"],"is_preprint":false},{"year":2008,"finding":"UBQLN2 (PLIC-2) is a negative regulator of GPCR endocytosis. Overexpression delays ligand-induced endocytosis of V2 vasopressin receptor and β2-adrenergic receptor by inhibiting their concentration in clathrin-coated pits, without affecting arrestin-3 membrane recruitment. The UBL domain of PLIC-2 is required for endocytic inhibition. PLIC-2 preferentially binds UIM-containing endocytic adaptors Eps15 and Epsin over PLIC-1.","method":"Overexpression/knockdown with live-cell endocytosis assays, domain deletion analysis, co-immunoprecipitation","journal":"Molecular biology of the cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — depletion confirmed endogenous function, domain mutants tested, binding partners identified, single lab","pmids":["18199683"],"is_preprint":false},{"year":2018,"finding":"UBQLN2 undergoes liquid-liquid phase separation (LLPS) at physiological conditions driven by multivalent weak interactions in its STI1-II low-complexity region. Oligomerization is required for LLPS and stress-induced cytoplasmic puncta formation in cells. Ubiquitin or polyubiquitin binding disrupts UBQLN2 LLPS, serving as a molecular switch between condensed and dispersed phases.","method":"NMR spectroscopy, in vitro LLPS assay, deletion mutant analysis, live-cell imaging, fluorescence microscopy","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1 / Strong — NMR structural mapping plus in vitro reconstitution plus cellular imaging, multiple orthogonal methods in one study","pmids":["29526694"],"is_preprint":false},{"year":2018,"finding":"ALS-linked mutations in the Pxx domain of UBQLN2 differentially enhance oligomerization, lower the saturation concentration for LLPS, and promote solid-like/viscoelastic morphological changes to UBQLN2 liquid assemblies in a position- and amino acid-dependent manner. Ubiquitin disassembles all LLPS-induced mutant UBQLN2 aggregates.","method":"Size-exclusion chromatography, analytical ultracentrifugation, NMR spectroscopy, microscopy","journal":"Structure","confidence":"High","confidence_rationale":"Tier 1 / Moderate — multiple biophysical methods (SEC, AUC, NMR, microscopy) in single lab with multiple mutants systematically compared","pmids":["30982635"],"is_preprint":false},{"year":2018,"finding":"UBQLN2 self-assembly into liquid droplets and amyloid aggregates is regulated by reciprocal modulation between its UBL and UBA domains. A pathogenic missense mutation impairs droplet dynamics and favors amyloid-like aggregation associated with neurotoxicity.","method":"In vitro protein analysis (LLPS, amyloid assays), fluorescence imaging, cellular and neuronal models, transgenic mouse models","journal":"PNAS","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — in vitro reconstitution plus cell/neuron/mouse models with functional readouts, multiple orthogonal methods","pmids":["30333186"],"is_preprint":false},{"year":2018,"finding":"The MTM1-UBQLN2 complex recognizes and guides misfolded intermediate filament proteins desmin and vimentin to the proteasome for degradation prior to aggregate formation in muscle cells, providing cytoskeletal integrity.","method":"Co-immunoprecipitation, knockdown/knockout studies in muscle cells, proteasome substrate assays, electron microscopy","journal":"Nature cell biology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — complex identified by Co-IP and validated by loss-of-function with defined substrate and cellular phenotype, published in rigorous journal","pmids":["29358706"],"is_preprint":false},{"year":2019,"finding":"The UBQLN2 UBL domain binds to hRpn10 (proteasome receptor) with 25-fold higher affinity for the N-terminal UIM-1 over UIM-2, exploiting additional contacts from the longer UIM-1 helix. NMR structure of the hRpn10:UBQLN2 UBL complex was solved, defining the structural basis of shuttle factor delivery to the proteasome.","method":"NMR spectroscopy (structure determination), NMR titration assay (affinity measurement)","journal":"Journal of molecular biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — NMR structure with quantitative affinity measurements, rigorous structural study in single lab","pmids":["30664872"],"is_preprint":false},{"year":2019,"finding":"ALS/FTD mutant UBQLN2 proteins (P497H, P506T) inhibit ER-to-Golgi protein transport in neuronal cells, causing clustering of ER exit sites, disorganization and fragmentation of ERGIC and Golgi, activation of ER stress, and inhibition of ERAD.","method":"Fluorescence imaging of ER/Golgi markers, patient spinal cord immunostaining, ER stress markers (Western blot), functional transport assay","journal":"Cellular and molecular life sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple imaging and biochemical assays in cell models plus patient tissue, single lab","pmids":["31802140"],"is_preprint":false},{"year":2020,"finding":"UBQLN2 functions in autophagy by regulating autophagosome acidification. Knockout of UBQLN2 in HeLa cells reduces autophagic flux and autophagosome acidification; this is rescued by WT but not by ALS/FTD mutant UBQLN2. UBQLN2 interacts with ATP6v1g1 (V-ATPase subunit), and mutant UBQLN2 shows weaker binding and reduced ATP6v1g1 stability. Overexpression of ATP6v1g1 rescues the acidification defect in UBQLN2 knockout cells.","method":"UBQLN2 knockout (CRISPR), rescue experiments, autophagic flux assay, lysosomal pH assay, proteomic analysis, immunoblot, in vitro interaction assay","journal":"PNAS","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal methods (KO, rescue with WT vs mutant, proteomics, in vitro binding, functional pH assay), replicated across cell types","pmids":["32513711"],"is_preprint":false},{"year":2021,"finding":"UBQLN2 is recruited to polyubiquitinated mitochondria via its UBA domain after Parkin-dependent ubiquitination of damaged mitochondria. UBQLN2 cooperates with HSP70 to promote UPS-driven degradation of outer mitochondrial membrane (OMM) proteins, causing OMM rupture that triggers autophagosomal recognition of inner mitochondrial membrane receptor PHB2. ALS/FTD UBQLN2 mutations impair this mitophagy pathway.","method":"Co-immunoprecipitation, mitophagy assays, domain deletion analysis, primary neuron cultures, mutant analysis","journal":"EMBO reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP, functional mitophagy assays, mutant comparison, single lab","pmids":["37501540"],"is_preprint":false},{"year":2021,"finding":"UBQLN2 knockouts in HeLa cells show defects in mitochondrial protein import: TIMM44 mislocalizes to abnormal foci. ALS/FTD UBQLN2 mutants bind TIMM44 more weakly than WT UBQLN2 by in vitro binding assay. OXPHOS deficits and TIMM44 targeting defects are rescued by WT but not ALS/FTD mutant UBQLN2, indicating a loss-of-function mechanism in mitochondrial import.","method":"UBQLN2 knockout, in vitro binding assay, OXPHOS functional assay, immunofluorescence for TIMM44 targeting, rescue experiments","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — KO, in vitro binding, functional mitochondrial assays, rescue with WT vs mutant, single lab","pmids":["33891006"],"is_preprint":false},{"year":2021,"finding":"UBQLN2 recognizes HSP70 ubiquitination, facilitating UBQLN2-HSP70-poly-GA complex formation and promoting poly-GA degradation. ALS/FTD-linked UBQLN2 mutants fail to bind HSP70 and cannot clear poly-GA aggregates. Disruption of the UBQLN2-HSP70 interaction inhibits poly-GA clearance in C9-ALS/FTD iPSC-derived neurons.","method":"Co-immunoprecipitation, in vitro binding, iPSC-derived neuron experiments, animal model behavioral assays, HSP70 enhancer (17AAG) treatment","journal":"Neuron","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal methods (Co-IP, in vitro binding, patient iPSC neurons, animal model) converging on same mechanism","pmids":["33991504"],"is_preprint":false},{"year":2021,"finding":"UBL and UBA domains of UBQLN2 contribute asymmetrically to LLPS: UBA domain removal inhibits LLPS while UBL domain removal enhances LLPS. NMR spectroscopy revealed novel non-canonical interactions between the UBL domain and disordered STI1-I and C-terminal residues 555–570, in addition to the canonical UBL:UBA interaction.","method":"NMR spectroscopy, domain deletion constructs, in vitro LLPS assay","journal":"Protein science","confidence":"High","confidence_rationale":"Tier 1 / Moderate — NMR structural mapping with multiple domain deletion constructs, mechanistically informative single-lab study","pmids":["34029402"],"is_preprint":false},{"year":2022,"finding":"RTL8 proteins interact with UBQLN2 (confirmed by MS, in vitro pulldown, and in vivo mouse brain Co-IP) and promote nuclear translocation of UBQLN2 to ubiquitin-enriched subnuclear structures containing protein quality control components. RTL8 specifically affects UBQLN2 but not UBQLN1 or UBQLN4 nuclear localization. UBQLN2 preferentially stabilizes RTL8 levels compared to other UBQLNs.","method":"Mass spectrometry interactome screen, in vitro pulldown with recombinant proteins, co-immunoprecipitation from mouse brain, live-cell imaging, immunofluorescence","journal":"Cellular and molecular life sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — MS discovery plus reciprocal Co-IP in vivo plus live imaging with functional localization consequence, single lab","pmids":["35247097"],"is_preprint":false},{"year":2022,"finding":"UBQLN2 undergoes a reversible temperature-induced conformational switch (detected by intrinsic tryptophan fluorescence) that increases binding to HSPA1B (HSP70) at 42°C. ALS/FTD mutant UBQLN2 proteins have attenuated conformational switching. UBQLN2 binds more avidly to K63 than K48 polyubiquitin chains. UBQLN2 binds directly to LC3 (autophagosome membrane protein). UBQLN2 homodimerizes and heterodimerizes with UBQLN1.","method":"Fluorescence spectroscopy (tryptophan), in vitro binding assays, polyubiquitin chain binding assay, LC3 pulldown, dimerization assays","journal":"Biochimica et biophysica acta. General subjects","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple in vitro binding methods, mutant comparisons, single lab","pmids":["36423739"],"is_preprint":false},{"year":2023,"finding":"UBQLN2 regulates PEG10 gag-pol (a domesticated retrotransposon protein) through proteasomal degradation in human cells and tissues. PEG10 gag-pol self-cleaves to generate a nucleocapsid fragment that localizes to the nucleus and alters gene expression. PEG10 gag-pol is elevated in spinal cord from ALS patients versus controls.","method":"Cell-based protein degradation assays, subcellular fractionation, RNA-seq/gene expression analysis, immunohistochemistry of ALS patient tissue","journal":"eLife","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional cell assays plus patient tissue analysis, single lab","pmids":["36951542"],"is_preprint":false},{"year":2023,"finding":"PolyQ-expanded Htt-N552 and Atx-3 sequester UBQLN2 into inclusions through the UBA domain of UBQLN2 and conjugated ubiquitin on the aggregated proteins, demonstrating that UBQLN2 recruitment to inclusions is ubiquitin-dependent.","method":"Co-immunoprecipitation, domain deletion analysis (UBA domain requirement), cell-based inclusion assay","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — Co-IP and domain deletion in cell model, single lab","pmids":["29401586"],"is_preprint":false},{"year":2024,"finding":"Polyubiquitinated substrates induce UBQLN2 phase separation and incorporate into UBQLN2 condensates in a chain linkage-dependent manner: K63-linked substrates most strongly promote condensation, K48-linked substrates least. Proteasome activity toward K63 and mixed-linkage substrates is inhibited within condensates, and substrates are protected from deubiquitinases by phase separation.","method":"Sedimentation assays, microscopy, in vitro LLPS assay with polyubiquitinated substrates, proteasome activity assay in condensates","journal":"PNAS","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with multiple chain linkages, functional proteasome activity assay within condensates, multiple orthogonal methods","pmids":["39121161"],"is_preprint":false},{"year":2025,"finding":"UBQLN2-mediated degradation of PEG10 gag-pol requires the E3 ubiquitin ligase UBE3A: UBE3A ubiquitinates gag-pol on key lysine residues in the pol region, and UBE3A cannot regulate gag-pol in the absence of UBQLN2. UBQLN2 binds PEG10 (both gag and gag-pol) independently of their ubiquitylation status, but only gag-pol is degraded in a UBQLN2-, ubiquitin-, and proteasome-dependent fashion.","method":"Knockdown/knockout of UBQLN2 and UBE3A, lysine mutation of PEG10, cycloheximide chase, proteasome inhibitor treatment, co-immunoprecipitation","journal":"Journal of cell science","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — multiple mechanistic experiments (KO, rescue, site-directed mutagenesis, inhibitor assays) establishing stepwise degradation model","pmids":["41234208"],"is_preprint":false},{"year":2025,"finding":"UBQLN2 is ubiquitylated on lysine residues in its N-terminal UBL domain; the UBL domain stabilizes UBQLN2 and protects it from proteasomal degradation. Fusion of ubiquitin to the UBQLN2 N-terminus increases its propensity to localize in puncta, suggesting ubiquitylation of the UBL domain regulates UBQLN2 abundance and condensate localization.","method":"Mass spectrometry (ubiquitylation site mapping), lysine mutagenesis, proteasome inhibitor assay, ubiquitin fusion constructs with microscopy","journal":"Biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — MS-confirmed ubiquitylation sites, functional mutagenesis, single lab","pmids":["41428212"],"is_preprint":false},{"year":2025,"finding":"UBQLN2 has a unique ability to protect substrates from proteasomal degradation (in addition to promoting degradation), and substrate stabilization correlates with recruitment of E3 ligases including SCFbxo7 to UBQLN2 condensates. ALS-linked mutants with altered phase separation also show defects in substrate stabilization. APP is also protected from degradation by UBQLN2 condensate formation.","method":"Triple-knockout cell lines with single paralog rescue (isogenic background), substrate degradation assays, E3 ligase co-IP, phase separation assays","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — isogenic TKO rescue system with multiple substrates and E3 ligase Co-IP, preprint not yet peer-reviewed","pmids":["40631187"],"is_preprint":true},{"year":2025,"finding":"PEG10, a core stress granule component, drives recruitment of UBQLN2 to stress granules, but only when RTL8 is present (RTL8 enables UBQLN2-PEG10 complex formation). Changes in UBQLN2, RTL8, or PEG10 levels remodel kinetics of stress granule disassembly and translation recovery.","method":"Co-immunoprecipitation, live-cell imaging of stress granule dynamics, stress granule composition proteomics, genetic manipulation of RTL8/PEG10 levels","journal":"Science advances","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP, live imaging, proteomic composition, functional assays, single lab","pmids":["40680123"],"is_preprint":false},{"year":2020,"finding":"UBQLN2 interacts with TBK1; co-expression of UBQLN2 with TBK1 elevates TBK1 protein levels and phosphorylation of TBK1 and IRF3 in a dose-dependent manner, promoting IFN-β production via the TBK1-IRF3 pathway. ALS/FTD-mutant UBQLN2 reduces TBK1 phosphorylation and impairs IRF3/p62/OPTN binding to TBK1.","method":"Co-immunoprecipitation, IRF3/IRF7 knockout cells (CRISPR), phosphorylation assays, IFN-β production assay","journal":"Cells","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP, KO cells, functional signaling assay, single lab","pmids":["32413959"],"is_preprint":false},{"year":2026,"finding":"UBQLN2 mediates proteasomal degradation of ILVBL (acetolactate synthase-like protein) and ALDH3A2 (aldehyde dehydrogenase involved in mitochondrial lipid catabolism); ALS/FTD UBQLN2 mutations impair degradation of these substrates leading to lipid metabolic dysfunction and neurodegeneration in iPSC-derived neurons, organoids, and mice.","method":"Multi-omic analysis of iPSC-derived neurons, cycloheximide chase, proteasome inhibitor assays, substrate degradation rescue experiments in neurons/organoids/mice","journal":"Nature neuroscience","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — multi-omic discovery plus in vitro degradation assays plus in vivo rescue in multiple model systems","pmids":["41912662"],"is_preprint":false},{"year":2026,"finding":"TRIM32 and UBQLN2 together with p62 form condensates (dependent on TRIM32 E3 ligase activity) that capture client proteins including TDP-43 and ANXA11 via the UBQLN2 STI1 domain. TRIM32 promotes amyloid aggregation of TDP-43, an effect exacerbated by pathogenic UBQLN2 mutation. TRIM32 co-localizes with pTDP-43 inclusions in human neurodegenerative disease brains.","method":"Co-immunoprecipitation, condensate formation assays, FRAP, E3 ligase activity assays, fluorescence microscopy, immunohistochemistry in human brain tissue","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple biochemical and imaging methods, human tissue validation, but preprint and single lab","pmids":["41727138"],"is_preprint":true},{"year":2026,"finding":"TRIM9 and TRIM26 E3 ubiquitin ligases selectively interact with and ubiquitinate ALS-mutant UBQLN2P497H (but not WT or P497S) and promote proteasomal degradation of a C-terminal UBQLN2 fragment generated specifically from P497H mutant; individual knockdown of TRIM9 or TRIM26 increases accumulation of this fragment.","method":"APEX2 proximity labeling, co-immunoprecipitation, siRNA knockdown, fractionation assay, proteasome inhibitor assay","journal":"ACS chemical biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — proximity proteomics validated by Co-IP, functional knockdown assays, single lab","pmids":["41582437"],"is_preprint":false},{"year":2017,"finding":"ALS-linked UBQLN2 mutations cause disrupted binding with HSP70 and impaired autophagic pathway in patient lymphoblasts. HSP70 binding occurs through the UBQLN2 STI1 domain regions, and the PXX repeat region is important for this interaction.","method":"Patient lymphoblast analysis, co-immunoprecipitation (HSP70 binding assay), autophagic pathway assay","journal":"Neurobiology of aging","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — Co-IP in patient-derived cells plus functional autophagy assay, single lab, limited mechanistic depth","pmids":["28716533"],"is_preprint":false},{"year":2023,"finding":"The Pxx (proline-rich) region of UBQLN2 confers unique temperature-dependent LLPS behavior absent in UBQLN1 and UBQLN4. Short N-terminal disordered regions of UBQLN1, UBQLN2, and UBQLN4 inhibit phase separation via electrostatic interactions. STI1-II is essential for baseline puncta formation in cells under all conditions, while both STI1 domains are required for heat stress-induced condensate formation.","method":"In vitro LLPS assay (turbidity, microscopy), domain deletion constructs, live-cell imaging","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — in vitro reconstitution and cell imaging, preprint, single lab","pmids":["37808720"],"is_preprint":true},{"year":2025,"finding":"UBQLN2 liquid droplets catalyze α-synuclein fibril formation in vitro and in cells; during liquid-to-gel/solid transition of UBQLN2 droplets, α-synuclein within droplets converts to pathogenic fibrils. UBQLN2 co-localizes with Lewy bodies in substantia nigra of Parkinson's disease patients. The small molecule SO286 inhibits UBQLN2 self-association and its interaction with α-synuclein by binding to the STI1 domain.","method":"In vitro LLPS and fibril formation assay, live-cell imaging, immunohistochemistry of PD patient brain sections, small molecule inhibitor characterization","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — in vitro reconstitution plus cell imaging plus patient tissue, preprint, single lab","pmids":["bio_10.1101_2025.03.17.643602"],"is_preprint":true}],"current_model":"UBQLN2 is a ubiquitin-binding shuttle protein with a UBL domain (binds proteasome receptor hRpn10/Rpn10), UBA domain (binds ubiquitin/polyubiquitin, preferentially K63-linked), and central STI1 domains (bind HSP70 chaperones and substrates); it delivers ubiquitinated and misfolded client proteins to the 26S proteasome by cooperating with HSP70-HSP110 disaggregase machinery, regulates autophagosome acidification via interaction with ATP6v1g1 (V-ATPase subunit), participates in Parkin-dependent mitophagy by promoting OMM protein degradation, undergoes liquid-liquid phase separation mediated by its STI1-II region—modulated by ubiquitin binding and ALS-linked Pxx mutations—which regulates substrate fate in a polyubiquitin chain-linkage-dependent manner, interacts with UBXD8 for ERAD, negatively regulates GPCR endocytosis via its UBL domain, is recruited to stress granules through RTL8-PEG10, facilitates UBE3A-dependent degradation of PEG10 gag-pol, and can mediate substrate stabilization through E3 ligase recruitment to condensates; ALS-causing mutations consistently impair HSP70 binding, aggregate clearance, autophagy, mitochondrial import, and phase separation dynamics."},"narrative":{"mechanistic_narrative":"UBQLN2 is a ubiquitin-binding shuttle factor that couples client recognition to the 26S proteasome, serving as a central node in cellular protein quality control [PMID:27477512, PMID:30664872]. It engages the proteasome through its UBL domain, which binds the receptor hRpn10 with strong preference for the N-terminal UIM-1 helix [PMID:30664872], while its UBA domain binds polyubiquitin with selectivity for K63-linked chains and recognizes ubiquitin conjugated to aggregated proteins [PMID:36423739, PMID:29401586]. Acting together with the HSP70-HSP110 disaggregase machinery, UBQLN2 recognizes client-bound and ubiquitinated HSP70 to deliver misfolded proteins for proteasomal clearance, a route operative even in the nucleus where autophagy is absent [PMID:27477512, PMID:33991504]. Its STI1 low-complexity region drives liquid-liquid phase separation under physiological and stress conditions, a behavior switched off by ubiquitin/polyubiquitin binding and tuned by reciprocal UBL:UBA contacts [PMID:29526694, PMID:34029402]; substrate fate within these condensates is governed by polyubiquitin chain linkage, with K63 chains promoting condensation and protecting substrates from the proteasome and deubiquitinases [PMID:39121161]. Beyond degradation, UBQLN2 can stabilize substrates by recruiting E3 ligases such as SCFbxo7 to condensates [PMID:40631187]. UBQLN2 has defined substrates and pathways including ERAD via UBXD8 [PMID:24215460], TDP-43 clearance [PMID:23541532], autophagosome acidification via the V-ATPase subunit ATP6v1g1 [PMID:32513711], Parkin-dependent mitophagy and mitochondrial protein import via TIMM44 [PMID:37501540, PMID:33891006], and UBE3A-dependent degradation of the retrotransposon-derived PEG10 gag-pol [PMID:41234208]. ALS/FTD-causing mutations, clustered in the Pxx region, consistently impair HSP70 binding, aggregate and substrate clearance, autophagy, mitochondrial function, and alter phase-separation dynamics toward solid-like aggregates [PMID:27477512, PMID:30982635, PMID:30333186, PMID:32513711, PMID:33991504, PMID:28716533], establishing UBQLN2 dysfunction as a driver of motor neuron degeneration.","teleology":[{"year":2008,"claim":"Before its quality-control role was defined, UBQLN2 was shown to act at the membrane, establishing it as a negative regulator of receptor endocytosis through its UBL domain.","evidence":"Overexpression/knockdown live-cell endocytosis assays with domain deletion and Co-IP in receptor-expressing cells","pmids":["18199683"],"confidence":"Medium","gaps":["Mechanism of UBL-dependent inhibition of clathrin-coated pit concentration unresolved","Physiological relevance to neurodegeneration not addressed"]},{"year":2011,"claim":"The founding ALS link established that UBQLN2 mutations impair degradation of ubiquitinated proteins, connecting the protein to ubiquitin-proteasome dysfunction and aggregation.","evidence":"Functional degradation assays in patient-derived cells","pmids":["21857683"],"confidence":"Medium","gaps":["Molecular step in the UPS that is disrupted not pinpointed","Direct substrates not identified"]},{"year":2013,"claim":"Specific clients and pathways were assigned, showing UBQLN2 binds TDP-43 with high affinity to promote its clearance and partners with UBXD8 for ER-associated degradation.","evidence":"Quantitative in vitro binding (KD), Co-IP, and ERAD/TDP-43 clearance assays in cells","pmids":["23541532","24215460"],"confidence":"Medium","gaps":["Whether TDP-43 binding requires ubiquitination not resolved","In vivo contribution of UBXD8 axis untested"]},{"year":2016,"claim":"The core delivery mechanism was defined: UBQLN2 recognizes client-bound HSP70 and links the HSP70-HSP110 disaggregase to the proteasome, with ALS mutants defective in HSP70 binding and aggregate clearance, including in the nucleus.","evidence":"In vitro reconstitution, Co-IP, cellular aggregate clearance, and mouse behavioral assays","pmids":["27477512"],"confidence":"High","gaps":["Stoichiometry of the HSP70-UBQLN2-proteasome handoff not defined","Determinants of nuclear vs cytoplasmic routing unclear"]},{"year":2017,"claim":"The HSP70 binding interface and mutation sensitivity were mapped, localizing chaperone engagement to the STI1/PXX regions and tying mutant defects to autophagy impairment.","evidence":"Co-IP and autophagy assays in patient lymphoblasts","pmids":["28716533"],"confidence":"Medium","gaps":["Residue-level HSP70 contacts not resolved","Causality between HSP70 loss and autophagy defect not separated"]},{"year":2018,"claim":"UBQLN2 was shown to phase separate via its STI1-II low-complexity region as a ubiquitin-switchable process, providing a biophysical framework for both its function and pathological aggregation.","evidence":"NMR, in vitro LLPS reconstitution, deletion analysis, and live-cell imaging; ALS Pxx-mutant biophysics by SEC/AUC/NMR; amyloid and transgenic mouse models","pmids":["29526694","30982635","30333186"],"confidence":"High","gaps":["In vivo functional output of condensates not directly measured","How ubiquitin disassembly couples to substrate handoff unclear"]},{"year":2018,"claim":"A new substrate axis was uncovered: the MTM1-UBQLN2 complex routes misfolded desmin and vimentin to the proteasome to preserve cytoskeletal integrity.","evidence":"Co-IP, knockdown/knockout in muscle cells, proteasome substrate assays, EM","pmids":["29358706"],"confidence":"High","gaps":["Relevance of MTM1 partnership to neuronal UBQLN2 function unknown","Recognition determinants for intermediate filaments undefined"]},{"year":2019,"claim":"The structural basis of proteasome delivery was solved, defining UBL:hRpn10 UIM-1 recognition; in parallel ALS mutants were shown to disrupt ER-to-Golgi transport.","evidence":"NMR structure and titration of hRpn10:UBL complex; ER/Golgi imaging and ER stress markers in neuronal cells and patient tissue","pmids":["30664872","31802140"],"confidence":"High","gaps":["Whether secretory-pathway defect is direct or downstream of UPS collapse unresolved"]},{"year":2020,"claim":"UBQLN2 was placed in autophagy and innate immune signaling, regulating autophagosome acidification via ATP6v1g1 and modulating TBK1-IRF3 signaling.","evidence":"CRISPR knockout with WT/mutant rescue, autophagic flux and lysosomal pH assays, proteomics; Co-IP and IFN-β/phosphorylation assays in IRF-knockout cells","pmids":["32513711","32413959"],"confidence":"High","gaps":["How UBQLN2 stabilizes ATP6v1g1 mechanistically unclear","Physiological role of TBK1 modulation in disease untested"]},{"year":2021,"claim":"UBQLN2 was tied to mitochondrial quality control on two fronts: UBA-dependent recruitment to Parkin-ubiquitinated mitochondria for OMM protein degradation, and a loss-of-function role in mitochondrial protein import via TIMM44.","evidence":"Co-IP, mitophagy assays, domain deletion, primary neurons; KO with in vitro TIMM44 binding, OXPHOS assays, and WT/mutant rescue","pmids":["37501540","33891006"],"confidence":"Medium","gaps":["Direct vs indirect role in import not fully separated","Single-lab findings without reciprocal validation"]},{"year":2021,"claim":"Recognition of ubiquitinated HSP70 was shown to drive clearance of the C9orf72 dipeptide poly-GA, with mutants failing to bind HSP70 and clear aggregates in patient iPSC neurons; biophysical work defined a temperature-induced conformational switch and K63>K48 ubiquitin and LC3 binding.","evidence":"Co-IP, in vitro binding, iPSC-neuron and animal models, HSP70 enhancer treatment; tryptophan fluorescence, chain-binding and LC3 pulldown assays","pmids":["33991504","36423739"],"confidence":"High","gaps":["Structural basis of conformational switch undefined","Functional consequence of LC3 binding not established"]},{"year":2021,"claim":"The domain logic of phase separation was refined, showing UBL and UBA contribute asymmetrically through canonical and newly identified non-canonical contacts.","evidence":"NMR with domain deletion constructs and in vitro LLPS assays","pmids":["34029402"],"confidence":"High","gaps":["Cellular relevance of non-canonical UBL contacts not tested"]},{"year":2022,"claim":"A regulator of UBQLN2 subcellular targeting was identified: RTL8 promotes UBQLN2 nuclear translocation to ubiquitin-enriched quality-control structures, selectively among ubiquilins.","evidence":"MS interactome, in vitro pulldown, in vivo mouse brain Co-IP, live imaging","pmids":["35247097"],"confidence":"Medium","gaps":["Mechanism of selectivity for UBQLN2 over paralogs unknown","Functional output of nuclear targeting not quantified"]},{"year":2023,"claim":"UBQLN2 was linked to control of the domesticated retrotransposon protein PEG10 gag-pol via proteasomal degradation, with elevated gag-pol in ALS patient spinal cord.","evidence":"Cell-based degradation assays, subcellular fractionation, RNA-seq, ALS tissue IHC","pmids":["36951542"],"confidence":"Medium","gaps":["E3 ligase and recognition determinants not yet identified in this study","Whether gag-pol accumulation is cause or consequence of disease unclear"]},{"year":2023,"claim":"Recruitment to disease inclusions was shown to be ubiquitin-dependent, with polyQ aggregates sequestering UBQLN2 through its UBA domain.","evidence":"Co-IP and UBA-deletion analysis in cell-based inclusion assays","pmids":["29401586"],"confidence":"Medium","gaps":["Single-lab cell model only","Consequence of sequestration for UBQLN2 function not measured"]},{"year":2024,"claim":"Substrate fate within condensates was shown to be linkage-encoded: K63 chains drive condensation and shield substrates from the proteasome and deubiquitinases, revealing condensates as a regulatory rather than purely degradative compartment.","evidence":"Sedimentation, microscopy, in vitro LLPS with defined polyubiquitinated substrates, proteasome activity assays in condensates","pmids":["39121161"],"confidence":"High","gaps":["How condensate-sequestered substrates are eventually released or degraded unclear","In-cell relevance of in vitro linkage selectivity untested"]},{"year":2025,"claim":"The PEG10 degradation pathway was assembled stepwise, showing UBE3A ubiquitinates gag-pol on pol-region lysines and that degradation requires both UBE3A and UBQLN2, while binding is ubiquitination-independent.","evidence":"KO of UBQLN2/UBE3A, lysine mutagenesis, cycloheximide chase, proteasome inhibition, Co-IP","pmids":["41234208"],"confidence":"High","gaps":["Why only gag-pol and not gag is degraded mechanistically unresolved"]},{"year":2025,"claim":"Autoregulation was uncovered: ubiquitylation of UBQLN2's own UBL domain stabilizes the protein and influences condensate localization, indicating self-regulation of abundance.","evidence":"MS ubiquitylation-site mapping, lysine mutagenesis, proteasome inhibition, ubiquitin-fusion microscopy","pmids":["41428212"],"confidence":"Medium","gaps":["Responsible E3 ligase(s) not identified","Single-lab finding"]},{"year":2025,"claim":"A non-canonical protective function was defined: UBQLN2 can stabilize substrates such as APP by recruiting E3 ligases including SCFbxo7 to condensates, with phase-separation-altering ALS mutants impaired in this activity.","evidence":"Isogenic triple-knockout with single-paralog rescue, substrate degradation assays, E3 Co-IP, phase separation assays (preprint)","pmids":["40631187"],"confidence":"Medium","gaps":["Preprint, not peer-reviewed","Mechanism distinguishing stabilization from degradation outcomes unclear"]},{"year":2026,"claim":"New metabolic substrates were identified, with UBQLN2 degrading ILVBL and ALDH3A2 and mutant-driven failure causing lipid metabolic dysfunction and neurodegeneration across multiple models.","evidence":"Multi-omics in iPSC neurons, cycloheximide chase, proteasome inhibition, rescue in neurons/organoids/mice","pmids":["41912662"],"confidence":"High","gaps":["Direct vs indirect recognition of these substrates not fully established"]},{"year":2026,"claim":"Condensate partnerships with E3 ligases were extended, showing TRIM32 (and earlier TRIM9/TRIM26 toward mutant protein) form quality-control condensates capturing TDP-43 and ANXA11 via the STI1 domain, modulating aggregation.","evidence":"Co-IP, condensate/FRAP assays, E3 activity assays, human brain IHC (TRIM32 preprint); APEX2 proximity labeling and knockdown for TRIM9/TRIM26","pmids":["41727138","41582437"],"confidence":"Medium","gaps":["TRIM32 study is a preprint","How E3 recruitment biases capture vs degradation undefined"]},{"year":2025,"claim":"UBQLN2 was implicated beyond ALS, with droplet liquid-to-solid transition catalyzing α-synuclein fibril formation and colocalization with Lewy bodies, plus a small-molecule inhibitor of STI1-mediated self-association.","evidence":"In vitro LLPS/fibril assays, live imaging, PD brain IHC, inhibitor characterization (preprint)","pmids":["bio_10.1101_2025.03.17.643602"],"confidence":"Medium","gaps":["Preprint, not peer-reviewed","Causal role of UBQLN2 in Parkinson's pathology not established in vivo"]},{"year":null,"claim":"How UBQLN2 toggles between promoting degradation and protecting substrates within condensates, and how this balance is set by ubiquitin chain linkage, E3 recruitment, and ALS mutations in vivo, remains the central open question.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model linking condensate state to substrate fate in cells","Determinants selecting degradation vs stabilization E3 partners unknown","In vivo measurement of condensate function in neurons lacking"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[3,14]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[3,9]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[20,23]},{"term_id":"GO:0140313","term_label":"molecular sequestering activity","supporting_discovery_ids":[20,23]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[5,11]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[3,16]},{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[12,13]},{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[1,10]}],"pathway":[{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[3,9]},{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[11,12]},{"term_id":"R-HSA-8953854","term_label":"Metabolism of RNA","supporting_discovery_ids":[20]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[0,26]}],"complexes":["UBQLN2-HSP70-HSP110 disaggregase machinery","MTM1-UBQLN2 complex","TRIM32-UBQLN2-p62 condensate"],"partners":["HSPA1B","RPN10","UBXD8","ATP6V1G1","TIMM44","RTL8","PEG10","UBE3A"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9UHD9","full_name":"Ubiquilin-2","aliases":["Chap1","DSK2 homolog","Protein linking IAP with cytoskeleton 2","PLIC-2","hPLIC-2","Ubiquitin-like product Chap1/Dsk2"],"length_aa":624,"mass_kda":65.7,"function":"Plays an important role in the regulation of different protein degradation mechanisms and pathways including ubiquitin-proteasome system (UPS), autophagy and the endoplasmic reticulum-associated protein degradation (ERAD) pathway. Mediates the proteasomal targeting of misfolded or accumulated proteins for degradation by binding (via UBA domain) to their polyubiquitin chains and by interacting (via ubiquitin-like domain) with the subunits of the proteasome (PubMed:10983987). Plays a role in the ERAD pathway via its interaction with ER-localized proteins FAF2/UBXD8 and HERPUD1 and may form a link between the polyubiquitinated ERAD substrates and the proteasome (PubMed:18307982, PubMed:24215460). Involved in the regulation of macroautophagy and autophagosome formation; required for maturation of autophagy-related protein LC3 from the cytosolic form LC3-I to the membrane-bound form LC3-II and may assist in the maturation of autophagosomes to autolysosomes by mediating autophagosome-lysosome fusion (PubMed:19148225, PubMed:20529957). Negatively regulates the endocytosis of GPCR receptors: AVPR2 and ADRB2, by specifically reducing the rate at which receptor-arrestin complexes concentrate in clathrin-coated pits (CCPs) (PubMed:18199683)","subcellular_location":"Cytoplasm; Nucleus; Membrane; Cytoplasmic vesicle, autophagosome","url":"https://www.uniprot.org/uniprotkb/Q9UHD9/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/UBQLN2","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"DYNLL1","stoichiometry":0.2},{"gene":"PSMD12","stoichiometry":0.2},{"gene":"PSMD3","stoichiometry":0.2},{"gene":"PSMD6","stoichiometry":0.2},{"gene":"SEM1","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/UBQLN2","total_profiled":1310},"omim":[{"mim_id":"619140","title":"NEDD4-BINDING PROTEIN 3; N4BP3","url":"https://www.omim.org/entry/619140"},{"mim_id":"619139","title":"NEDD4-BINDING PROTEIN 2; N4BP2","url":"https://www.omim.org/entry/619139"},{"mim_id":"619138","title":"NEDD4-BINDING PROTEIN 1; N4BP1","url":"https://www.omim.org/entry/619138"},{"mim_id":"616719","title":"SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 21; SCAR21","url":"https://www.omim.org/entry/616719"},{"mim_id":"616437","title":"FRONTOTEMPORAL DEMENTIA AND/OR AMYOTROPHIC LATERAL SCLEROSIS 3; FTDALS3","url":"https://www.omim.org/entry/616437"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Cytosol","reliability":"Supported"},{"location":"Plasma membrane","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/UBQLN2"},"hgnc":{"alias_symbol":["Chap1","Dsk2","RIHFB2157","LIC-2","CHAP1/DSK2","PLIC-2","N4BP4","PLIC2"],"prev_symbol":[]},"alphafold":{"accession":"Q9UHD9","domains":[{"cath_id":"3.10.20.90","chopping":"33-103","consensus_level":"high","plddt":87.6266,"start":33,"end":103},{"cath_id":"-","chopping":"178-264","consensus_level":"medium","plddt":68.0391,"start":178,"end":264},{"cath_id":"-","chopping":"395-469","consensus_level":"medium","plddt":69.6967,"start":395,"end":469},{"cath_id":"1.10.8.10","chopping":"578-624","consensus_level":"medium","plddt":82.1494,"start":578,"end":624}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9UHD9","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9UHD9-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9UHD9-F1-predicted_aligned_error_v6.png","plddt_mean":61.03},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=UBQLN2","jax_strain_url":"https://www.jax.org/strain/search?query=UBQLN2"},"sequence":{"accession":"Q9UHD9","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9UHD9.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9UHD9/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9UHD9"}},"corpus_meta":[{"pmid":"21857683","id":"PMC_21857683","title":"Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia.","date":"2011","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/21857683","citation_count":956,"is_preprint":false},{"pmid":"29526694","id":"PMC_29526694","title":"Ubiquitin Modulates Liquid-Liquid Phase Separation of UBQLN2 via Disruption of Multivalent Interactions.","date":"2018","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/29526694","citation_count":282,"is_preprint":false},{"pmid":"27477512","id":"PMC_27477512","title":"UBQLN2 Mediates Autophagy-Independent Protein Aggregate Clearance by the Proteasome.","date":"2016","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/27477512","citation_count":244,"is_preprint":false},{"pmid":"22717235","id":"PMC_22717235","title":"UBQLN2/ubiquilin 2 mutation and pathology in familial amyotrophic lateral sclerosis.","date":"2012","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/22717235","citation_count":141,"is_preprint":false},{"pmid":"31319884","id":"PMC_31319884","title":"Key role of UBQLN2 in pathogenesis of amyotrophic lateral sclerosis and frontotemporal dementia.","date":"2019","source":"Acta neuropathologica communications","url":"https://pubmed.ncbi.nlm.nih.gov/31319884","citation_count":97,"is_preprint":false},{"pmid":"30982635","id":"PMC_30982635","title":"ALS-Linked Mutations Affect UBQLN2 Oligomerization and Phase Separation in a Position- and Amino Acid-Dependent Manner.","date":"2019","source":"Structure (London, England : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/30982635","citation_count":78,"is_preprint":false},{"pmid":"27834214","id":"PMC_27834214","title":"Motor neuron disease, TDP-43 pathology, and memory deficits in mice expressing ALS-FTD-linked UBQLN2 mutations.","date":"2016","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/27834214","citation_count":77,"is_preprint":false},{"pmid":"32513711","id":"PMC_32513711","title":"ALS/FTD mutations in UBQLN2 impede autophagy by reducing autophagosome acidification through loss of function.","date":"2020","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/32513711","citation_count":72,"is_preprint":false},{"pmid":"25388785","id":"PMC_25388785","title":"Pathogenic Ubqln2 gains toxic properties to induce neuron death.","date":"2014","source":"Acta neuropathologica","url":"https://pubmed.ncbi.nlm.nih.gov/25388785","citation_count":66,"is_preprint":false},{"pmid":"25246588","id":"PMC_25246588","title":"Dendritic spinopathy in transgenic mice expressing ALS/dementia-linked mutant UBQLN2.","date":"2014","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/25246588","citation_count":64,"is_preprint":false},{"pmid":"24215460","id":"PMC_24215460","title":"Pathogenic mutation of UBQLN2 impairs its interaction with UBXD8 and disrupts endoplasmic reticulum-associated protein degradation.","date":"2013","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24215460","citation_count":60,"is_preprint":false},{"pmid":"24771548","id":"PMC_24771548","title":"UBQLN2 mutation causing heterogeneous X-linked dominant neurodegeneration.","date":"2014","source":"Annals of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/24771548","citation_count":55,"is_preprint":false},{"pmid":"23541532","id":"PMC_23541532","title":"Ubiquilin-2 (UBQLN2) binds with high affinity to the C-terminal region of TDP-43 and modulates TDP-43 levels in H4 cells: characterization of inhibition by nucleic acids and 4-aminoquinolines.","date":"2013","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/23541532","citation_count":54,"is_preprint":false},{"pmid":"30333186","id":"PMC_30333186","title":"Mutant UBQLN2 promotes toxicity by modulating intrinsic self-assembly.","date":"2018","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/30333186","citation_count":51,"is_preprint":false},{"pmid":"28716533","id":"PMC_28716533","title":"Novel UBQLN2 mutations linked to amyotrophic lateral sclerosis and atypical hereditary spastic paraplegia phenotype through defective HSP70-mediated proteolysis.","date":"2017","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/28716533","citation_count":50,"is_preprint":false},{"pmid":"22246868","id":"PMC_22246868","title":"UBQLN2/P62 cellular recycling pathways in amyotrophic lateral sclerosis and frontotemporal dementia.","date":"2012","source":"Muscle & nerve","url":"https://pubmed.ncbi.nlm.nih.gov/22246868","citation_count":44,"is_preprint":false},{"pmid":"33991504","id":"PMC_33991504","title":"UBQLN2-HSP70 axis reduces poly-Gly-Ala aggregates and alleviates behavioral defects in the C9ORF72 animal model.","date":"2021","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/33991504","citation_count":41,"is_preprint":false},{"pmid":"29358706","id":"PMC_29358706","title":"The MTM1-UBQLN2-HSP complex mediates degradation of misfolded intermediate filaments in skeletal muscle.","date":"2018","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/29358706","citation_count":40,"is_preprint":false},{"pmid":"34273246","id":"PMC_34273246","title":"UBQLN proteins in health and disease with a focus on UBQLN2 in ALS/FTD.","date":"2021","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/34273246","citation_count":39,"is_preprint":false},{"pmid":"30664872","id":"PMC_30664872","title":"Structure of hRpn10 Bound to UBQLN2 UBL Illustrates Basis for Complementarity between Shuttle Factors and Substrates at the Proteasome.","date":"2019","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/30664872","citation_count":39,"is_preprint":false},{"pmid":"30409191","id":"PMC_30409191","title":"Mutant UBQLN2P497H in motor neurons leads to ALS-like phenotypes and defective autophagy in rats.","date":"2018","source":"Acta neuropathologica communications","url":"https://pubmed.ncbi.nlm.nih.gov/30409191","citation_count":38,"is_preprint":false},{"pmid":"22560112","id":"PMC_22560112","title":"UBQLN2 mutations are rare in French and French-Canadian amyotrophic lateral sclerosis.","date":"2012","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/22560112","citation_count":38,"is_preprint":false},{"pmid":"33277362","id":"PMC_33277362","title":"Global proteomics of Ubqln2-based murine models of ALS.","date":"2020","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/33277362","citation_count":37,"is_preprint":false},{"pmid":"23312802","id":"PMC_23312802","title":"Explorative genetic study of UBQLN2 and PFN1 in an extended Flanders-Belgian cohort of frontotemporal lobar degeneration patients.","date":"2013","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/23312802","citation_count":34,"is_preprint":false},{"pmid":"18199683","id":"PMC_18199683","title":"The ubiquitin-like protein PLIC-2 is a negative regulator of G protein-coupled receptor endocytosis.","date":"2008","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/18199683","citation_count":32,"is_preprint":false},{"pmid":"23944734","id":"PMC_23944734","title":"Clinical variability and female penetrance in X-linked familial FTD/ALS caused by a P506S mutation in UBQLN2.","date":"2013","source":"Amyotrophic lateral sclerosis & frontotemporal degeneration","url":"https://pubmed.ncbi.nlm.nih.gov/23944734","citation_count":32,"is_preprint":false},{"pmid":"31802140","id":"PMC_31802140","title":"Amyotrophic lateral sclerosis-linked UBQLN2 mutants inhibit endoplasmic reticulum to Golgi transport, leading to Golgi fragmentation and ER stress.","date":"2019","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/31802140","citation_count":32,"is_preprint":false},{"pmid":"27456931","id":"PMC_27456931","title":"Increased Ubqln2 expression causes neuron death in transgenic rats.","date":"2016","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/27456931","citation_count":31,"is_preprint":false},{"pmid":"22169395","id":"PMC_22169395","title":"Mutations in UBQLN2 are rare in French amyotrophic lateral sclerosis.","date":"2011","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/22169395","citation_count":31,"is_preprint":false},{"pmid":"37501540","id":"PMC_37501540","title":"UBQLN2 and HSP70 participate in Parkin-mediated mitophagy by facilitating outer mitochondrial membrane rupture.","date":"2023","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/37501540","citation_count":30,"is_preprint":false},{"pmid":"36951542","id":"PMC_36951542","title":"UBQLN2 restrains the domesticated retrotransposon PEG10 to maintain neuronal health in ALS.","date":"2023","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/36951542","citation_count":30,"is_preprint":false},{"pmid":"34029402","id":"PMC_34029402","title":"Previously uncharacterized interactions between the folded and intrinsically disordered domains impart asymmetric effects on UBQLN2 phase separation.","date":"2021","source":"Protein science : a publication of the Protein Society","url":"https://pubmed.ncbi.nlm.nih.gov/34029402","citation_count":30,"is_preprint":false},{"pmid":"29161404","id":"PMC_29161404","title":"Mutation-dependent aggregation and toxicity in a Drosophila model for UBQLN2-associated ALS.","date":"2018","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/29161404","citation_count":29,"is_preprint":false},{"pmid":"29401586","id":"PMC_29401586","title":"PolyQ-expanded huntingtin and ataxin-3 sequester ubiquitin adaptors hHR23B and UBQLN2 into aggregates via conjugated ubiquitin.","date":"2018","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/29401586","citation_count":27,"is_preprint":false},{"pmid":"24684794","id":"PMC_24684794","title":"Mutations in UBQLN2 and SIGMAR1 genes are rare in Korean patients with amyotrophic lateral sclerosis.","date":"2014","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/24684794","citation_count":25,"is_preprint":false},{"pmid":"34129687","id":"PMC_34129687","title":"ALS-linked mutations impair UBQLN2 stress-induced biomolecular condensate assembly in cells.","date":"2021","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/34129687","citation_count":23,"is_preprint":false},{"pmid":"32653673","id":"PMC_32653673","title":"Modeling UBQLN2-mediated neurodegenerative disease in mice: Shared and divergent properties of wild type and mutant UBQLN2 in phase separation, subcellular localization, altered proteostasis pathways, and selective cytotoxicity.","date":"2020","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/32653673","citation_count":23,"is_preprint":false},{"pmid":"30377984","id":"PMC_30377984","title":"Neuronal Expression of UBQLN2P497H Exacerbates TDP-43 Pathology in TDP-43G348C Mice through Interaction with Ubiquitin.","date":"2018","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/30377984","citation_count":22,"is_preprint":false},{"pmid":"33891006","id":"PMC_33891006","title":"ALS/FTD mutations in UBQLN2 are linked to mitochondrial dysfunction through loss-of-function in mitochondrial protein import.","date":"2021","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/33891006","citation_count":21,"is_preprint":false},{"pmid":"26141599","id":"PMC_26141599","title":"Differential recruitment of UBQLN2 to nuclear inclusions in the polyglutamine diseases HD and SCA3.","date":"2015","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/26141599","citation_count":21,"is_preprint":false},{"pmid":"23980626","id":"PMC_23980626","title":"Iron, oxidative stress, and virulence: roles of iron-sensitive transcription factor Sre1 and the redox sensor ChAp1 in the maize pathogen Cochliobolus heterostrophus.","date":"2013","source":"Molecular plant-microbe interactions : MPMI","url":"https://pubmed.ncbi.nlm.nih.gov/23980626","citation_count":20,"is_preprint":false},{"pmid":"27480424","id":"PMC_27480424","title":"C9ORF72 and UBQLN2 mutations are causes of amyotrophic lateral sclerosis in New Zealand: a genetic and pathologic study using banked human brain tissue.","date":"2016","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/27480424","citation_count":18,"is_preprint":false},{"pmid":"30348461","id":"PMC_30348461","title":"Striking phenotypic variation in a family with the P506S UBQLN2 mutation including amyotrophic lateral sclerosis, spastic paraplegia, and frontotemporal dementia.","date":"2018","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/30348461","citation_count":18,"is_preprint":false},{"pmid":"39121161","id":"PMC_39121161","title":"Phase separation of polyubiquitinated proteins in UBQLN2 condensates controls substrate fate.","date":"2024","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/39121161","citation_count":16,"is_preprint":false},{"pmid":"35247097","id":"PMC_35247097","title":"RTL8 promotes nuclear localization of UBQLN2 to subnuclear compartments associated with protein quality control.","date":"2022","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/35247097","citation_count":15,"is_preprint":false},{"pmid":"31167121","id":"PMC_31167121","title":"Lou Gehrig's Disease (ALS): UBQLN2 Mutations Strike Out of Phase.","date":"2019","source":"Structure (London, England : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/31167121","citation_count":15,"is_preprint":false},{"pmid":"38472280","id":"PMC_38472280","title":"Pathogenic mutations in UBQLN2 exhibit diverse aggregation propensity and neurotoxicity.","date":"2024","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/38472280","citation_count":14,"is_preprint":false},{"pmid":"37039476","id":"PMC_37039476","title":"Axon guidance genes modulate neurotoxicity of ALS-associated UBQLN2.","date":"2023","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/37039476","citation_count":14,"is_preprint":false},{"pmid":"23745603","id":"PMC_23745603","title":"Role of the transcription factor ChAP1 in cytoplasmic redox homeostasis: imaging with a genetically encoded sensor in the maize pathogen Cochliobolus heterostrophus.","date":"2013","source":"Molecular plant pathology","url":"https://pubmed.ncbi.nlm.nih.gov/23745603","citation_count":14,"is_preprint":false},{"pmid":"33028421","id":"PMC_33028421","title":"Overexpression of UBQLN1 reduces neuropathology in the P497S UBQLN2 mouse model of ALS/FTD.","date":"2020","source":"Acta neuropathologica communications","url":"https://pubmed.ncbi.nlm.nih.gov/33028421","citation_count":14,"is_preprint":false},{"pmid":"27703430","id":"PMC_27703430","title":"Early Impairment of Synaptic and Intrinsic Excitability in Mice Expressing ALS/Dementia-Linked Mutant UBQLN2.","date":"2016","source":"Frontiers in cellular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/27703430","citation_count":14,"is_preprint":false},{"pmid":"35082119","id":"PMC_35082119","title":"Disrupting the Balance of Protein Quality Control Protein UBQLN2 Accelerates Tau Proteinopathy.","date":"2022","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/35082119","citation_count":13,"is_preprint":false},{"pmid":"25179229","id":"PMC_25179229","title":"UBQLN2 variant of unknown significance in frontotemporal lobar degeneration.","date":"2014","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/25179229","citation_count":13,"is_preprint":false},{"pmid":"38703371","id":"PMC_38703371","title":"Hippocampal aggregation signatures of pathogenic UBQLN2 in amyotrophic lateral sclerosis and frontotemporal dementia.","date":"2024","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/38703371","citation_count":12,"is_preprint":false},{"pmid":"23582661","id":"PMC_23582661","title":"Screening UBQLN-2 in French frontotemporal lobar degeneration and frontotemporal lobar degeneration-amyotrophic lateral sclerosis patients.","date":"2013","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/23582661","citation_count":12,"is_preprint":false},{"pmid":"24164316","id":"PMC_24164316","title":"Genetic interaction of the stress response factors ChAP1 and Skn7 in the maize pathogen Cochliobolus heterostrophus.","date":"2013","source":"FEMS microbiology letters","url":"https://pubmed.ncbi.nlm.nih.gov/24164316","citation_count":11,"is_preprint":false},{"pmid":"32413959","id":"PMC_32413959","title":"UBQLN2 Promotes the Production of Type I Interferon via the TBK1-IRF3 Pathway.","date":"2020","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/32413959","citation_count":10,"is_preprint":false},{"pmid":"38115557","id":"PMC_38115557","title":"Distribution of ubiquilin 2 and TDP-43 aggregates throughout the CNS in UBQLN2 p.T487I-linked amyotrophic lateral sclerosis and frontotemporal dementia.","date":"2023","source":"Brain pathology (Zurich, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/38115557","citation_count":10,"is_preprint":false},{"pmid":"22676852","id":"PMC_22676852","title":"UBQLN2 in familial amyotrophic lateral sclerosis in The Netherlands.","date":"2012","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/22676852","citation_count":9,"is_preprint":false},{"pmid":"40680123","id":"PMC_40680123","title":"Endogenous retrovirus-like proteins recruit UBQLN2 to stress granules and shape their functional biology.","date":"2025","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/40680123","citation_count":8,"is_preprint":false},{"pmid":"32731393","id":"PMC_32731393","title":"The Impact of ALS-Associated Genes hnRNPA1, MATR3, VCP and UBQLN2 on the Severity of TDP-43 Aggregation.","date":"2020","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/32731393","citation_count":8,"is_preprint":false},{"pmid":"23973441","id":"PMC_23973441","title":"UBQLN2 mutations are not a frequent cause of amyotrophic lateral sclerosis in Ireland.","date":"2013","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/23973441","citation_count":8,"is_preprint":false},{"pmid":"28125704","id":"PMC_28125704","title":"No Evidence for Pathogenic Role of UBQLN2 Mutations in Sporadic Amyotrophic Lateral Sclerosis in the Mainland Chinese Population.","date":"2017","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/28125704","citation_count":8,"is_preprint":false},{"pmid":"28286874","id":"PMC_28286874","title":"Investigation of the adaptor protein PLIC-2 in multiple pathways.","date":"2017","source":"Biochemistry and biophysics reports","url":"https://pubmed.ncbi.nlm.nih.gov/28286874","citation_count":7,"is_preprint":false},{"pmid":"35777956","id":"PMC_35777956","title":"Multi-omics profiling identifies a deregulated FUS-MAP1B axis in ALS/FTD-associated UBQLN2 mutants.","date":"2022","source":"Life science alliance","url":"https://pubmed.ncbi.nlm.nih.gov/35777956","citation_count":7,"is_preprint":false},{"pmid":"40631187","id":"PMC_40631187","title":"E3 ligase recruitment by UBQLN2 protects substrates from proteasomal degradation.","date":"2025","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/40631187","citation_count":7,"is_preprint":false},{"pmid":"33919255","id":"PMC_33919255","title":"Impaired 26S Proteasome Assembly Precedes Neuronal Loss in Mutant UBQLN2 Rats.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33919255","citation_count":7,"is_preprint":false},{"pmid":"36310223","id":"PMC_36310223","title":"A Spectrophotometric Turbidity Assay to Study Liquid-Liquid Phase Separation of UBQLN2 In Vitro.","date":"2023","source":"Methods in molecular biology (Clifton, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/36310223","citation_count":6,"is_preprint":false},{"pmid":"40663766","id":"PMC_40663766","title":"UBQLN2 in neurodegenerative disease: mechanistic insights and emerging therapeutic potential.","date":"2025","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/40663766","citation_count":5,"is_preprint":false},{"pmid":"36423739","id":"PMC_36423739","title":"UBQLN2 undergoes a reversible temperature-induced conformational switch that regulates binding with HSPA1B: ALS/FTD mutations cripple the switch but do not destroy HSPA1B binding.","date":"2022","source":"Biochimica et biophysica acta. General subjects","url":"https://pubmed.ncbi.nlm.nih.gov/36423739","citation_count":5,"is_preprint":false},{"pmid":"35063704","id":"PMC_35063704","title":"Towards a molecular understanding of the overlapping and distinct roles of UBQLN1 and UBQLN2 in lung cancer progression and metastasis.","date":"2022","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/35063704","citation_count":5,"is_preprint":false},{"pmid":"33780087","id":"PMC_33780087","title":"Serpin neuropathology in the P497S UBQLN2 mouse model of ALS/FTD.","date":"2021","source":"Brain pathology (Zurich, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/33780087","citation_count":5,"is_preprint":false},{"pmid":"36644234","id":"PMC_36644234","title":"Silencing UBQLN2 Enhances the Radiosensitivity of Esophageal Squamous Cell Carcinoma (ESCC) via Activating p38 MAPK.","date":"2023","source":"Journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/36644234","citation_count":4,"is_preprint":false},{"pmid":"31312934","id":"PMC_31312934","title":"The AP-1-like transcription factor ChAP1 balances tolerance and cell death in the response of the maize pathogen Cochliobolus heterostrophus to a plant phenolic.","date":"2019","source":"Current genetics","url":"https://pubmed.ncbi.nlm.nih.gov/31312934","citation_count":4,"is_preprint":false},{"pmid":"36232630","id":"PMC_36232630","title":"Damaged DNA Is an Early Event of Neurodegeneration in Induced Pluripotent Stem Cell-Derived Motoneurons with UBQLN2P497H Mutation.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36232630","citation_count":4,"is_preprint":false},{"pmid":"39769213","id":"PMC_39769213","title":"Chronic Oxidative Stress and Stress Granule Formation in UBQLN2 ALS Neurons: Insights into Neuronal Degeneration and Potential Therapeutic Targets.","date":"2024","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/39769213","citation_count":2,"is_preprint":false},{"pmid":"36310225","id":"PMC_36310225","title":"Neuronal Puncta/Aggregate Formation by WT and Mutant UBQLN2.","date":"2023","source":"Methods in molecular biology (Clifton, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/36310225","citation_count":2,"is_preprint":false},{"pmid":"36310224","id":"PMC_36310224","title":"An Optimized Stress Granule Detection Method: Investigation of UBQLN2 Effect on Stress Granule Formation.","date":"2023","source":"Methods in molecular biology (Clifton, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/36310224","citation_count":2,"is_preprint":false},{"pmid":"27723099","id":"PMC_27723099","title":"New transgenic ALS/FTD models on the rat-walk: An Editorial Highlight for 'Increased Ubqln2 expression causes neuron death in transgenic rats'.","date":"2016","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/27723099","citation_count":2,"is_preprint":false},{"pmid":"32290710","id":"PMC_32290710","title":"First case of an UBQLN2 gene mutation causing frontotemporal dementia preceded by adult onset psychiatric symptoms.","date":"2020","source":"Amyotrophic lateral sclerosis & frontotemporal degeneration","url":"https://pubmed.ncbi.nlm.nih.gov/32290710","citation_count":2,"is_preprint":false},{"pmid":"41234208","id":"PMC_41234208","title":"UBQLN2 is necessary for UBE3A-mediated proteasomal degradation of the domesticated retroelement PEG10.","date":"2025","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/41234208","citation_count":1,"is_preprint":false},{"pmid":"37808720","id":"PMC_37808720","title":"Short N-terminal disordered regions and the proline-rich domain are major regulators of phase transitions for full-length UBQLN1, UBQLN2 and UBQLN4.","date":"2023","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/37808720","citation_count":1,"is_preprint":false},{"pmid":"38559018","id":"PMC_38559018","title":"Phase separation of polyubiquitinated proteins in UBQLN2 condensates controls substrate fate.","date":"2024","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/38559018","citation_count":1,"is_preprint":false},{"pmid":"33789365","id":"PMC_33789365","title":"[Association between rare UBQLN2 variants and amyotrophic lateral sclerosis in Chinese population].","date":"2021","source":"Zhonghua yi xue za zhi","url":"https://pubmed.ncbi.nlm.nih.gov/33789365","citation_count":1,"is_preprint":false},{"pmid":"39628898","id":"PMC_39628898","title":"Analysis of translatomic changes in the Ubqln2 model of ALS reveals that motor neurons express muscle-associated genes in non-disease states.","date":"2024","source":"Frontiers in neurology","url":"https://pubmed.ncbi.nlm.nih.gov/39628898","citation_count":1,"is_preprint":false},{"pmid":"41912662","id":"PMC_41912662","title":"UBQLN2 links proteotoxicity with lipid metabolism in neurodegeneration.","date":"2026","source":"Nature neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/41912662","citation_count":0,"is_preprint":false},{"pmid":"41016645","id":"PMC_41016645","title":"A meta-analysis of genetic variant pathogenicity and sex differences in UBQLN2-linked amyotrophic lateral sclerosis and frontotemporal dementia.","date":"2025","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/41016645","citation_count":0,"is_preprint":false},{"pmid":"41727138","id":"PMC_41727138","title":"TRIM32-UBQLN2-p62 axis promotes TDP-43 inclusion formation and amyloid aggregation through shuttle condensates.","date":"2026","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/41727138","citation_count":0,"is_preprint":false},{"pmid":"41428212","id":"PMC_41428212","title":"The Importance of UBQLN2 Ubiquitylation for Its Turnover and Localization.","date":"2025","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/41428212","citation_count":0,"is_preprint":false},{"pmid":"38943019","id":"PMC_38943019","title":"Two new cases with the UBQLN2 gene mutation in Han Chinese.","date":"2024","source":"Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology","url":"https://pubmed.ncbi.nlm.nih.gov/38943019","citation_count":0,"is_preprint":false},{"pmid":"40841583","id":"PMC_40841583","title":"A Japanese familial spastic paraplegia associated with a missense UBQLN2 variant.","date":"2025","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/40841583","citation_count":0,"is_preprint":false},{"pmid":"39395630","id":"PMC_39395630","title":"ERO1A inhibition mitigates neuronal ER stress and ameliorates UBQLN2ALS phenotypes in Drosophila melanogaster.","date":"2024","source":"Progress in neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/39395630","citation_count":0,"is_preprint":false},{"pmid":"41582437","id":"PMC_41582437","title":"TRIM9 and TRIM26 Interact with UBQLN2P497H to Modulate Its Proteasomal Degradation.","date":"2026","source":"ACS chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/41582437","citation_count":0,"is_preprint":false},{"pmid":"41959388","id":"PMC_41959388","title":"STI1 domains coordinate partitioning of UBQLN2 into stress-induced condensates.","date":"2026","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/41959388","citation_count":0,"is_preprint":false},{"pmid":"41561437","id":"PMC_41561437","title":"Interactome screening implicates BAG6 as a suppressor of UBQLN2 misfolding in ALS/FTD.","date":"2026","source":"Frontiers in molecular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/41561437","citation_count":0,"is_preprint":false},{"pmid":"41278912","id":"PMC_41278912","title":"Interactome screening implicates BAG6 as a suppressor of UBQLN2 misfolding in ALS-dementia.","date":"2025","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/41278912","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.03.28.646022","title":"UBQLN2 facilitates degradation of the retrotransposon protein PEG10 via UBE3A activity","date":"2025-03-31","source":"bioRxiv","url":"https://doi.org/10.1101/2025.03.28.646022","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.03.17.643602","title":"Ubiquilin-2 liquid droplets catalyze α-synuclein fibril formation","date":"2025-03-20","source":"bioRxiv","url":"https://doi.org/10.1101/2025.03.17.643602","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.10.25.24316165","title":"A meta-analysis of genetic variant pathogenicity and sex differences in<i>UBQLN2</i>-linked amyotrophic lateral sclerosis and frontotemporal dementia","date":"2024-10-27","source":"bioRxiv","url":"https://doi.org/10.1101/2024.10.25.24316165","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.10.24.620053","title":"Endogenous retrovirus-like proteins recruit UBQLN2 to stress granules and alter their functional properties","date":"2024-10-25","source":"bioRxiv","url":"https://doi.org/10.1101/2024.10.24.620053","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":49775,"output_tokens":8237,"usd":0.13644,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":17866,"output_tokens":6669,"usd":0.128027,"stage2_stop_reason":"end_turn"},"total_usd":0.264467,"stage1_batch_id":"msgbatch_017qqVz33Ga63SCDwzb35XPb","stage2_batch_id":"msgbatch_01Scr2Ei9x4HJMiRGxwrmvLK","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2011,\n      \"finding\": \"UBQLN2 mutations impair ubiquitinated protein degradation. Functional analysis in patient-derived cells showed that ALS-linked UBQLN2 mutations lead to impairment of the protein degradation pathway, linking ubiquilin 2 abnormalities to defects in the ubiquitin-proteasome system and abnormal protein aggregation.\",\n      \"method\": \"Functional degradation assays in patient-derived cells\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional assay in patient cells, single lab, foundational study but limited mechanistic resolution in the abstract\",\n      \"pmids\": [\"21857683\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"UBQLN2 interacts with UBXD8 (an ER membrane protein involved in ERAD substrate translocation) both in vitro and in vivo via co-IP and in vitro binding assays; ALS-linked pathogenic mutation impairs this interaction, disrupting ER-associated protein degradation and causing greater accumulation of ERAD substrates.\",\n      \"method\": \"Co-immunoprecipitation, in vitro binding assay, ERAD substrate accumulation assay\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP plus in vitro binding plus functional ERAD assay, single lab\",\n      \"pmids\": [\"24215460\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"UBQLN2 binds directly to the C-terminal region of TDP-43 with high affinity (KD ~6–9 nM), as demonstrated by binding assays and co-IP in H4 cells. Overexpression of UBQLN2 enhances clearance of TDP-43 and C-terminal TDP-43 fragments, reducing their steady-state levels.\",\n      \"method\": \"In vitro binding assay (KD determination), co-immunoprecipitation, cell overexpression with immunoblot\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — quantitative in vitro binding plus Co-IP plus cell-based functional assay, single lab\",\n      \"pmids\": [\"23541532\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"UBQLN2 acts together with the HSP70-HSP110 disaggregase machinery to clear protein aggregates via the 26S proteasome, independent of autophagy. UBQLN2 recognizes client-bound HSP70 and links it to the proteasome. ALS-linked UBQLN2 mutations are defective in chaperone (HSP70) binding and impair aggregate clearance. This pathway is active in the nucleus where autophagy does not operate.\",\n      \"method\": \"In vitro reconstitution, co-immunoprecipitation, cellular aggregate clearance assays, mouse behavioral tests, nucleus-specific assays\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple orthogonal methods including in vitro reconstitution, Co-IP, functional cellular assays, and in vivo mouse models in a single rigorous study\",\n      \"pmids\": [\"27477512\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"UBQLN2 (PLIC-2) is a negative regulator of GPCR endocytosis. Overexpression delays ligand-induced endocytosis of V2 vasopressin receptor and β2-adrenergic receptor by inhibiting their concentration in clathrin-coated pits, without affecting arrestin-3 membrane recruitment. The UBL domain of PLIC-2 is required for endocytic inhibition. PLIC-2 preferentially binds UIM-containing endocytic adaptors Eps15 and Epsin over PLIC-1.\",\n      \"method\": \"Overexpression/knockdown with live-cell endocytosis assays, domain deletion analysis, co-immunoprecipitation\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — depletion confirmed endogenous function, domain mutants tested, binding partners identified, single lab\",\n      \"pmids\": [\"18199683\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"UBQLN2 undergoes liquid-liquid phase separation (LLPS) at physiological conditions driven by multivalent weak interactions in its STI1-II low-complexity region. Oligomerization is required for LLPS and stress-induced cytoplasmic puncta formation in cells. Ubiquitin or polyubiquitin binding disrupts UBQLN2 LLPS, serving as a molecular switch between condensed and dispersed phases.\",\n      \"method\": \"NMR spectroscopy, in vitro LLPS assay, deletion mutant analysis, live-cell imaging, fluorescence microscopy\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — NMR structural mapping plus in vitro reconstitution plus cellular imaging, multiple orthogonal methods in one study\",\n      \"pmids\": [\"29526694\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ALS-linked mutations in the Pxx domain of UBQLN2 differentially enhance oligomerization, lower the saturation concentration for LLPS, and promote solid-like/viscoelastic morphological changes to UBQLN2 liquid assemblies in a position- and amino acid-dependent manner. Ubiquitin disassembles all LLPS-induced mutant UBQLN2 aggregates.\",\n      \"method\": \"Size-exclusion chromatography, analytical ultracentrifugation, NMR spectroscopy, microscopy\",\n      \"journal\": \"Structure\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — multiple biophysical methods (SEC, AUC, NMR, microscopy) in single lab with multiple mutants systematically compared\",\n      \"pmids\": [\"30982635\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"UBQLN2 self-assembly into liquid droplets and amyloid aggregates is regulated by reciprocal modulation between its UBL and UBA domains. A pathogenic missense mutation impairs droplet dynamics and favors amyloid-like aggregation associated with neurotoxicity.\",\n      \"method\": \"In vitro protein analysis (LLPS, amyloid assays), fluorescence imaging, cellular and neuronal models, transgenic mouse models\",\n      \"journal\": \"PNAS\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — in vitro reconstitution plus cell/neuron/mouse models with functional readouts, multiple orthogonal methods\",\n      \"pmids\": [\"30333186\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"The MTM1-UBQLN2 complex recognizes and guides misfolded intermediate filament proteins desmin and vimentin to the proteasome for degradation prior to aggregate formation in muscle cells, providing cytoskeletal integrity.\",\n      \"method\": \"Co-immunoprecipitation, knockdown/knockout studies in muscle cells, proteasome substrate assays, electron microscopy\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — complex identified by Co-IP and validated by loss-of-function with defined substrate and cellular phenotype, published in rigorous journal\",\n      \"pmids\": [\"29358706\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"The UBQLN2 UBL domain binds to hRpn10 (proteasome receptor) with 25-fold higher affinity for the N-terminal UIM-1 over UIM-2, exploiting additional contacts from the longer UIM-1 helix. NMR structure of the hRpn10:UBQLN2 UBL complex was solved, defining the structural basis of shuttle factor delivery to the proteasome.\",\n      \"method\": \"NMR spectroscopy (structure determination), NMR titration assay (affinity measurement)\",\n      \"journal\": \"Journal of molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — NMR structure with quantitative affinity measurements, rigorous structural study in single lab\",\n      \"pmids\": [\"30664872\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ALS/FTD mutant UBQLN2 proteins (P497H, P506T) inhibit ER-to-Golgi protein transport in neuronal cells, causing clustering of ER exit sites, disorganization and fragmentation of ERGIC and Golgi, activation of ER stress, and inhibition of ERAD.\",\n      \"method\": \"Fluorescence imaging of ER/Golgi markers, patient spinal cord immunostaining, ER stress markers (Western blot), functional transport assay\",\n      \"journal\": \"Cellular and molecular life sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple imaging and biochemical assays in cell models plus patient tissue, single lab\",\n      \"pmids\": [\"31802140\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"UBQLN2 functions in autophagy by regulating autophagosome acidification. Knockout of UBQLN2 in HeLa cells reduces autophagic flux and autophagosome acidification; this is rescued by WT but not by ALS/FTD mutant UBQLN2. UBQLN2 interacts with ATP6v1g1 (V-ATPase subunit), and mutant UBQLN2 shows weaker binding and reduced ATP6v1g1 stability. Overexpression of ATP6v1g1 rescues the acidification defect in UBQLN2 knockout cells.\",\n      \"method\": \"UBQLN2 knockout (CRISPR), rescue experiments, autophagic flux assay, lysosomal pH assay, proteomic analysis, immunoblot, in vitro interaction assay\",\n      \"journal\": \"PNAS\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal methods (KO, rescue with WT vs mutant, proteomics, in vitro binding, functional pH assay), replicated across cell types\",\n      \"pmids\": [\"32513711\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"UBQLN2 is recruited to polyubiquitinated mitochondria via its UBA domain after Parkin-dependent ubiquitination of damaged mitochondria. UBQLN2 cooperates with HSP70 to promote UPS-driven degradation of outer mitochondrial membrane (OMM) proteins, causing OMM rupture that triggers autophagosomal recognition of inner mitochondrial membrane receptor PHB2. ALS/FTD UBQLN2 mutations impair this mitophagy pathway.\",\n      \"method\": \"Co-immunoprecipitation, mitophagy assays, domain deletion analysis, primary neuron cultures, mutant analysis\",\n      \"journal\": \"EMBO reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, functional mitophagy assays, mutant comparison, single lab\",\n      \"pmids\": [\"37501540\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"UBQLN2 knockouts in HeLa cells show defects in mitochondrial protein import: TIMM44 mislocalizes to abnormal foci. ALS/FTD UBQLN2 mutants bind TIMM44 more weakly than WT UBQLN2 by in vitro binding assay. OXPHOS deficits and TIMM44 targeting defects are rescued by WT but not ALS/FTD mutant UBQLN2, indicating a loss-of-function mechanism in mitochondrial import.\",\n      \"method\": \"UBQLN2 knockout, in vitro binding assay, OXPHOS functional assay, immunofluorescence for TIMM44 targeting, rescue experiments\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KO, in vitro binding, functional mitochondrial assays, rescue with WT vs mutant, single lab\",\n      \"pmids\": [\"33891006\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"UBQLN2 recognizes HSP70 ubiquitination, facilitating UBQLN2-HSP70-poly-GA complex formation and promoting poly-GA degradation. ALS/FTD-linked UBQLN2 mutants fail to bind HSP70 and cannot clear poly-GA aggregates. Disruption of the UBQLN2-HSP70 interaction inhibits poly-GA clearance in C9-ALS/FTD iPSC-derived neurons.\",\n      \"method\": \"Co-immunoprecipitation, in vitro binding, iPSC-derived neuron experiments, animal model behavioral assays, HSP70 enhancer (17AAG) treatment\",\n      \"journal\": \"Neuron\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal methods (Co-IP, in vitro binding, patient iPSC neurons, animal model) converging on same mechanism\",\n      \"pmids\": [\"33991504\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"UBL and UBA domains of UBQLN2 contribute asymmetrically to LLPS: UBA domain removal inhibits LLPS while UBL domain removal enhances LLPS. NMR spectroscopy revealed novel non-canonical interactions between the UBL domain and disordered STI1-I and C-terminal residues 555–570, in addition to the canonical UBL:UBA interaction.\",\n      \"method\": \"NMR spectroscopy, domain deletion constructs, in vitro LLPS assay\",\n      \"journal\": \"Protein science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — NMR structural mapping with multiple domain deletion constructs, mechanistically informative single-lab study\",\n      \"pmids\": [\"34029402\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"RTL8 proteins interact with UBQLN2 (confirmed by MS, in vitro pulldown, and in vivo mouse brain Co-IP) and promote nuclear translocation of UBQLN2 to ubiquitin-enriched subnuclear structures containing protein quality control components. RTL8 specifically affects UBQLN2 but not UBQLN1 or UBQLN4 nuclear localization. UBQLN2 preferentially stabilizes RTL8 levels compared to other UBQLNs.\",\n      \"method\": \"Mass spectrometry interactome screen, in vitro pulldown with recombinant proteins, co-immunoprecipitation from mouse brain, live-cell imaging, immunofluorescence\",\n      \"journal\": \"Cellular and molecular life sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — MS discovery plus reciprocal Co-IP in vivo plus live imaging with functional localization consequence, single lab\",\n      \"pmids\": [\"35247097\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"UBQLN2 undergoes a reversible temperature-induced conformational switch (detected by intrinsic tryptophan fluorescence) that increases binding to HSPA1B (HSP70) at 42°C. ALS/FTD mutant UBQLN2 proteins have attenuated conformational switching. UBQLN2 binds more avidly to K63 than K48 polyubiquitin chains. UBQLN2 binds directly to LC3 (autophagosome membrane protein). UBQLN2 homodimerizes and heterodimerizes with UBQLN1.\",\n      \"method\": \"Fluorescence spectroscopy (tryptophan), in vitro binding assays, polyubiquitin chain binding assay, LC3 pulldown, dimerization assays\",\n      \"journal\": \"Biochimica et biophysica acta. General subjects\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple in vitro binding methods, mutant comparisons, single lab\",\n      \"pmids\": [\"36423739\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"UBQLN2 regulates PEG10 gag-pol (a domesticated retrotransposon protein) through proteasomal degradation in human cells and tissues. PEG10 gag-pol self-cleaves to generate a nucleocapsid fragment that localizes to the nucleus and alters gene expression. PEG10 gag-pol is elevated in spinal cord from ALS patients versus controls.\",\n      \"method\": \"Cell-based protein degradation assays, subcellular fractionation, RNA-seq/gene expression analysis, immunohistochemistry of ALS patient tissue\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional cell assays plus patient tissue analysis, single lab\",\n      \"pmids\": [\"36951542\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"PolyQ-expanded Htt-N552 and Atx-3 sequester UBQLN2 into inclusions through the UBA domain of UBQLN2 and conjugated ubiquitin on the aggregated proteins, demonstrating that UBQLN2 recruitment to inclusions is ubiquitin-dependent.\",\n      \"method\": \"Co-immunoprecipitation, domain deletion analysis (UBA domain requirement), cell-based inclusion assay\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — Co-IP and domain deletion in cell model, single lab\",\n      \"pmids\": [\"29401586\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Polyubiquitinated substrates induce UBQLN2 phase separation and incorporate into UBQLN2 condensates in a chain linkage-dependent manner: K63-linked substrates most strongly promote condensation, K48-linked substrates least. Proteasome activity toward K63 and mixed-linkage substrates is inhibited within condensates, and substrates are protected from deubiquitinases by phase separation.\",\n      \"method\": \"Sedimentation assays, microscopy, in vitro LLPS assay with polyubiquitinated substrates, proteasome activity assay in condensates\",\n      \"journal\": \"PNAS\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with multiple chain linkages, functional proteasome activity assay within condensates, multiple orthogonal methods\",\n      \"pmids\": [\"39121161\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"UBQLN2-mediated degradation of PEG10 gag-pol requires the E3 ubiquitin ligase UBE3A: UBE3A ubiquitinates gag-pol on key lysine residues in the pol region, and UBE3A cannot regulate gag-pol in the absence of UBQLN2. UBQLN2 binds PEG10 (both gag and gag-pol) independently of their ubiquitylation status, but only gag-pol is degraded in a UBQLN2-, ubiquitin-, and proteasome-dependent fashion.\",\n      \"method\": \"Knockdown/knockout of UBQLN2 and UBE3A, lysine mutation of PEG10, cycloheximide chase, proteasome inhibitor treatment, co-immunoprecipitation\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — multiple mechanistic experiments (KO, rescue, site-directed mutagenesis, inhibitor assays) establishing stepwise degradation model\",\n      \"pmids\": [\"41234208\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"UBQLN2 is ubiquitylated on lysine residues in its N-terminal UBL domain; the UBL domain stabilizes UBQLN2 and protects it from proteasomal degradation. Fusion of ubiquitin to the UBQLN2 N-terminus increases its propensity to localize in puncta, suggesting ubiquitylation of the UBL domain regulates UBQLN2 abundance and condensate localization.\",\n      \"method\": \"Mass spectrometry (ubiquitylation site mapping), lysine mutagenesis, proteasome inhibitor assay, ubiquitin fusion constructs with microscopy\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — MS-confirmed ubiquitylation sites, functional mutagenesis, single lab\",\n      \"pmids\": [\"41428212\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"UBQLN2 has a unique ability to protect substrates from proteasomal degradation (in addition to promoting degradation), and substrate stabilization correlates with recruitment of E3 ligases including SCFbxo7 to UBQLN2 condensates. ALS-linked mutants with altered phase separation also show defects in substrate stabilization. APP is also protected from degradation by UBQLN2 condensate formation.\",\n      \"method\": \"Triple-knockout cell lines with single paralog rescue (isogenic background), substrate degradation assays, E3 ligase co-IP, phase separation assays\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — isogenic TKO rescue system with multiple substrates and E3 ligase Co-IP, preprint not yet peer-reviewed\",\n      \"pmids\": [\"40631187\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"PEG10, a core stress granule component, drives recruitment of UBQLN2 to stress granules, but only when RTL8 is present (RTL8 enables UBQLN2-PEG10 complex formation). Changes in UBQLN2, RTL8, or PEG10 levels remodel kinetics of stress granule disassembly and translation recovery.\",\n      \"method\": \"Co-immunoprecipitation, live-cell imaging of stress granule dynamics, stress granule composition proteomics, genetic manipulation of RTL8/PEG10 levels\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, live imaging, proteomic composition, functional assays, single lab\",\n      \"pmids\": [\"40680123\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"UBQLN2 interacts with TBK1; co-expression of UBQLN2 with TBK1 elevates TBK1 protein levels and phosphorylation of TBK1 and IRF3 in a dose-dependent manner, promoting IFN-β production via the TBK1-IRF3 pathway. ALS/FTD-mutant UBQLN2 reduces TBK1 phosphorylation and impairs IRF3/p62/OPTN binding to TBK1.\",\n      \"method\": \"Co-immunoprecipitation, IRF3/IRF7 knockout cells (CRISPR), phosphorylation assays, IFN-β production assay\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, KO cells, functional signaling assay, single lab\",\n      \"pmids\": [\"32413959\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"UBQLN2 mediates proteasomal degradation of ILVBL (acetolactate synthase-like protein) and ALDH3A2 (aldehyde dehydrogenase involved in mitochondrial lipid catabolism); ALS/FTD UBQLN2 mutations impair degradation of these substrates leading to lipid metabolic dysfunction and neurodegeneration in iPSC-derived neurons, organoids, and mice.\",\n      \"method\": \"Multi-omic analysis of iPSC-derived neurons, cycloheximide chase, proteasome inhibitor assays, substrate degradation rescue experiments in neurons/organoids/mice\",\n      \"journal\": \"Nature neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — multi-omic discovery plus in vitro degradation assays plus in vivo rescue in multiple model systems\",\n      \"pmids\": [\"41912662\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"TRIM32 and UBQLN2 together with p62 form condensates (dependent on TRIM32 E3 ligase activity) that capture client proteins including TDP-43 and ANXA11 via the UBQLN2 STI1 domain. TRIM32 promotes amyloid aggregation of TDP-43, an effect exacerbated by pathogenic UBQLN2 mutation. TRIM32 co-localizes with pTDP-43 inclusions in human neurodegenerative disease brains.\",\n      \"method\": \"Co-immunoprecipitation, condensate formation assays, FRAP, E3 ligase activity assays, fluorescence microscopy, immunohistochemistry in human brain tissue\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple biochemical and imaging methods, human tissue validation, but preprint and single lab\",\n      \"pmids\": [\"41727138\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"TRIM9 and TRIM26 E3 ubiquitin ligases selectively interact with and ubiquitinate ALS-mutant UBQLN2P497H (but not WT or P497S) and promote proteasomal degradation of a C-terminal UBQLN2 fragment generated specifically from P497H mutant; individual knockdown of TRIM9 or TRIM26 increases accumulation of this fragment.\",\n      \"method\": \"APEX2 proximity labeling, co-immunoprecipitation, siRNA knockdown, fractionation assay, proteasome inhibitor assay\",\n      \"journal\": \"ACS chemical biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — proximity proteomics validated by Co-IP, functional knockdown assays, single lab\",\n      \"pmids\": [\"41582437\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"ALS-linked UBQLN2 mutations cause disrupted binding with HSP70 and impaired autophagic pathway in patient lymphoblasts. HSP70 binding occurs through the UBQLN2 STI1 domain regions, and the PXX repeat region is important for this interaction.\",\n      \"method\": \"Patient lymphoblast analysis, co-immunoprecipitation (HSP70 binding assay), autophagic pathway assay\",\n      \"journal\": \"Neurobiology of aging\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — Co-IP in patient-derived cells plus functional autophagy assay, single lab, limited mechanistic depth\",\n      \"pmids\": [\"28716533\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"The Pxx (proline-rich) region of UBQLN2 confers unique temperature-dependent LLPS behavior absent in UBQLN1 and UBQLN4. Short N-terminal disordered regions of UBQLN1, UBQLN2, and UBQLN4 inhibit phase separation via electrostatic interactions. STI1-II is essential for baseline puncta formation in cells under all conditions, while both STI1 domains are required for heat stress-induced condensate formation.\",\n      \"method\": \"In vitro LLPS assay (turbidity, microscopy), domain deletion constructs, live-cell imaging\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — in vitro reconstitution and cell imaging, preprint, single lab\",\n      \"pmids\": [\"37808720\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"UBQLN2 liquid droplets catalyze α-synuclein fibril formation in vitro and in cells; during liquid-to-gel/solid transition of UBQLN2 droplets, α-synuclein within droplets converts to pathogenic fibrils. UBQLN2 co-localizes with Lewy bodies in substantia nigra of Parkinson's disease patients. The small molecule SO286 inhibits UBQLN2 self-association and its interaction with α-synuclein by binding to the STI1 domain.\",\n      \"method\": \"In vitro LLPS and fibril formation assay, live-cell imaging, immunohistochemistry of PD patient brain sections, small molecule inhibitor characterization\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — in vitro reconstitution plus cell imaging plus patient tissue, preprint, single lab\",\n      \"pmids\": [\"bio_10.1101_2025.03.17.643602\"],\n      \"is_preprint\": true\n    }\n  ],\n  \"current_model\": \"UBQLN2 is a ubiquitin-binding shuttle protein with a UBL domain (binds proteasome receptor hRpn10/Rpn10), UBA domain (binds ubiquitin/polyubiquitin, preferentially K63-linked), and central STI1 domains (bind HSP70 chaperones and substrates); it delivers ubiquitinated and misfolded client proteins to the 26S proteasome by cooperating with HSP70-HSP110 disaggregase machinery, regulates autophagosome acidification via interaction with ATP6v1g1 (V-ATPase subunit), participates in Parkin-dependent mitophagy by promoting OMM protein degradation, undergoes liquid-liquid phase separation mediated by its STI1-II region—modulated by ubiquitin binding and ALS-linked Pxx mutations—which regulates substrate fate in a polyubiquitin chain-linkage-dependent manner, interacts with UBXD8 for ERAD, negatively regulates GPCR endocytosis via its UBL domain, is recruited to stress granules through RTL8-PEG10, facilitates UBE3A-dependent degradation of PEG10 gag-pol, and can mediate substrate stabilization through E3 ligase recruitment to condensates; ALS-causing mutations consistently impair HSP70 binding, aggregate clearance, autophagy, mitochondrial import, and phase separation dynamics.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"UBQLN2 is a ubiquitin-binding shuttle factor that couples client recognition to the 26S proteasome, serving as a central node in cellular protein quality control [#3, #9]. It engages the proteasome through its UBL domain, which binds the receptor hRpn10 with strong preference for the N-terminal UIM-1 helix [#9], while its UBA domain binds polyubiquitin with selectivity for K63-linked chains and recognizes ubiquitin conjugated to aggregated proteins [#17, #19]. Acting together with the HSP70-HSP110 disaggregase machinery, UBQLN2 recognizes client-bound and ubiquitinated HSP70 to deliver misfolded proteins for proteasomal clearance, a route operative even in the nucleus where autophagy is absent [#3, #14]. Its STI1 low-complexity region drives liquid-liquid phase separation under physiological and stress conditions, a behavior switched off by ubiquitin/polyubiquitin binding and tuned by reciprocal UBL:UBA contacts [#5, #15]; substrate fate within these condensates is governed by polyubiquitin chain linkage, with K63 chains promoting condensation and protecting substrates from the proteasome and deubiquitinases [#20]. Beyond degradation, UBQLN2 can stabilize substrates by recruiting E3 ligases such as SCFbxo7 to condensates [#23]. UBQLN2 has defined substrates and pathways including ERAD via UBXD8 [#1], TDP-43 clearance [#2], autophagosome acidification via the V-ATPase subunit ATP6v1g1 [#11], Parkin-dependent mitophagy and mitochondrial protein import via TIMM44 [#12, #13], and UBE3A-dependent degradation of the retrotransposon-derived PEG10 gag-pol [#21]. ALS/FTD-causing mutations, clustered in the Pxx region, consistently impair HSP70 binding, aggregate and substrate clearance, autophagy, mitochondrial function, and alter phase-separation dynamics toward solid-like aggregates [#3, #6, #7, #11, #14, #29], establishing UBQLN2 dysfunction as a driver of motor neuron degeneration.\"\n,\n  \"teleology\": [\n    {\n      \"year\": 2008,\n      \"claim\": \"Before its quality-control role was defined, UBQLN2 was shown to act at the membrane, establishing it as a negative regulator of receptor endocytosis through its UBL domain.\",\n      \"evidence\": \"Overexpression/knockdown live-cell endocytosis assays with domain deletion and Co-IP in receptor-expressing cells\",\n      \"pmids\": [\"18199683\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of UBL-dependent inhibition of clathrin-coated pit concentration unresolved\", \"Physiological relevance to neurodegeneration not addressed\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"The founding ALS link established that UBQLN2 mutations impair degradation of ubiquitinated proteins, connecting the protein to ubiquitin-proteasome dysfunction and aggregation.\",\n      \"evidence\": \"Functional degradation assays in patient-derived cells\",\n      \"pmids\": [\"21857683\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular step in the UPS that is disrupted not pinpointed\", \"Direct substrates not identified\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Specific clients and pathways were assigned, showing UBQLN2 binds TDP-43 with high affinity to promote its clearance and partners with UBXD8 for ER-associated degradation.\",\n      \"evidence\": \"Quantitative in vitro binding (KD), Co-IP, and ERAD/TDP-43 clearance assays in cells\",\n      \"pmids\": [\"23541532\", \"24215460\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether TDP-43 binding requires ubiquitination not resolved\", \"In vivo contribution of UBXD8 axis untested\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"The core delivery mechanism was defined: UBQLN2 recognizes client-bound HSP70 and links the HSP70-HSP110 disaggregase to the proteasome, with ALS mutants defective in HSP70 binding and aggregate clearance, including in the nucleus.\",\n      \"evidence\": \"In vitro reconstitution, Co-IP, cellular aggregate clearance, and mouse behavioral assays\",\n      \"pmids\": [\"27477512\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry of the HSP70-UBQLN2-proteasome handoff not defined\", \"Determinants of nuclear vs cytoplasmic routing unclear\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"The HSP70 binding interface and mutation sensitivity were mapped, localizing chaperone engagement to the STI1/PXX regions and tying mutant defects to autophagy impairment.\",\n      \"evidence\": \"Co-IP and autophagy assays in patient lymphoblasts\",\n      \"pmids\": [\"28716533\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Residue-level HSP70 contacts not resolved\", \"Causality between HSP70 loss and autophagy defect not separated\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"UBQLN2 was shown to phase separate via its STI1-II low-complexity region as a ubiquitin-switchable process, providing a biophysical framework for both its function and pathological aggregation.\",\n      \"evidence\": \"NMR, in vitro LLPS reconstitution, deletion analysis, and live-cell imaging; ALS Pxx-mutant biophysics by SEC/AUC/NMR; amyloid and transgenic mouse models\",\n      \"pmids\": [\"29526694\", \"30982635\", \"30333186\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo functional output of condensates not directly measured\", \"How ubiquitin disassembly couples to substrate handoff unclear\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"A new substrate axis was uncovered: the MTM1-UBQLN2 complex routes misfolded desmin and vimentin to the proteasome to preserve cytoskeletal integrity.\",\n      \"evidence\": \"Co-IP, knockdown/knockout in muscle cells, proteasome substrate assays, EM\",\n      \"pmids\": [\"29358706\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relevance of MTM1 partnership to neuronal UBQLN2 function unknown\", \"Recognition determinants for intermediate filaments undefined\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"The structural basis of proteasome delivery was solved, defining UBL:hRpn10 UIM-1 recognition; in parallel ALS mutants were shown to disrupt ER-to-Golgi transport.\",\n      \"evidence\": \"NMR structure and titration of hRpn10:UBL complex; ER/Golgi imaging and ER stress markers in neuronal cells and patient tissue\",\n      \"pmids\": [\"30664872\", \"31802140\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether secretory-pathway defect is direct or downstream of UPS collapse unresolved\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"UBQLN2 was placed in autophagy and innate immune signaling, regulating autophagosome acidification via ATP6v1g1 and modulating TBK1-IRF3 signaling.\",\n      \"evidence\": \"CRISPR knockout with WT/mutant rescue, autophagic flux and lysosomal pH assays, proteomics; Co-IP and IFN-\\u03b2/phosphorylation assays in IRF-knockout cells\",\n      \"pmids\": [\"32513711\", \"32413959\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How UBQLN2 stabilizes ATP6v1g1 mechanistically unclear\", \"Physiological role of TBK1 modulation in disease untested\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"UBQLN2 was tied to mitochondrial quality control on two fronts: UBA-dependent recruitment to Parkin-ubiquitinated mitochondria for OMM protein degradation, and a loss-of-function role in mitochondrial protein import via TIMM44.\",\n      \"evidence\": \"Co-IP, mitophagy assays, domain deletion, primary neurons; KO with in vitro TIMM44 binding, OXPHOS assays, and WT/mutant rescue\",\n      \"pmids\": [\"37501540\", \"33891006\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs indirect role in import not fully separated\", \"Single-lab findings without reciprocal validation\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Recognition of ubiquitinated HSP70 was shown to drive clearance of the C9orf72 dipeptide poly-GA, with mutants failing to bind HSP70 and clear aggregates in patient iPSC neurons; biophysical work defined a temperature-induced conformational switch and K63>K48 ubiquitin and LC3 binding.\",\n      \"evidence\": \"Co-IP, in vitro binding, iPSC-neuron and animal models, HSP70 enhancer treatment; tryptophan fluorescence, chain-binding and LC3 pulldown assays\",\n      \"pmids\": [\"33991504\", \"36423739\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of conformational switch undefined\", \"Functional consequence of LC3 binding not established\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"The domain logic of phase separation was refined, showing UBL and UBA contribute asymmetrically through canonical and newly identified non-canonical contacts.\",\n      \"evidence\": \"NMR with domain deletion constructs and in vitro LLPS assays\",\n      \"pmids\": [\"34029402\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cellular relevance of non-canonical UBL contacts not tested\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"A regulator of UBQLN2 subcellular targeting was identified: RTL8 promotes UBQLN2 nuclear translocation to ubiquitin-enriched quality-control structures, selectively among ubiquilins.\",\n      \"evidence\": \"MS interactome, in vitro pulldown, in vivo mouse brain Co-IP, live imaging\",\n      \"pmids\": [\"35247097\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of selectivity for UBQLN2 over paralogs unknown\", \"Functional output of nuclear targeting not quantified\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"UBQLN2 was linked to control of the domesticated retrotransposon protein PEG10 gag-pol via proteasomal degradation, with elevated gag-pol in ALS patient spinal cord.\",\n      \"evidence\": \"Cell-based degradation assays, subcellular fractionation, RNA-seq, ALS tissue IHC\",\n      \"pmids\": [\"36951542\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"E3 ligase and recognition determinants not yet identified in this study\", \"Whether gag-pol accumulation is cause or consequence of disease unclear\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Recruitment to disease inclusions was shown to be ubiquitin-dependent, with polyQ aggregates sequestering UBQLN2 through its UBA domain.\",\n      \"evidence\": \"Co-IP and UBA-deletion analysis in cell-based inclusion assays\",\n      \"pmids\": [\"29401586\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab cell model only\", \"Consequence of sequestration for UBQLN2 function not measured\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Substrate fate within condensates was shown to be linkage-encoded: K63 chains drive condensation and shield substrates from the proteasome and deubiquitinases, revealing condensates as a regulatory rather than purely degradative compartment.\",\n      \"evidence\": \"Sedimentation, microscopy, in vitro LLPS with defined polyubiquitinated substrates, proteasome activity assays in condensates\",\n      \"pmids\": [\"39121161\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How condensate-sequestered substrates are eventually released or degraded unclear\", \"In-cell relevance of in vitro linkage selectivity untested\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"The PEG10 degradation pathway was assembled stepwise, showing UBE3A ubiquitinates gag-pol on pol-region lysines and that degradation requires both UBE3A and UBQLN2, while binding is ubiquitination-independent.\",\n      \"evidence\": \"KO of UBQLN2/UBE3A, lysine mutagenesis, cycloheximide chase, proteasome inhibition, Co-IP\",\n      \"pmids\": [\"41234208\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Why only gag-pol and not gag is degraded mechanistically unresolved\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Autoregulation was uncovered: ubiquitylation of UBQLN2's own UBL domain stabilizes the protein and influences condensate localization, indicating self-regulation of abundance.\",\n      \"evidence\": \"MS ubiquitylation-site mapping, lysine mutagenesis, proteasome inhibition, ubiquitin-fusion microscopy\",\n      \"pmids\": [\"41428212\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Responsible E3 ligase(s) not identified\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"A non-canonical protective function was defined: UBQLN2 can stabilize substrates such as APP by recruiting E3 ligases including SCFbxo7 to condensates, with phase-separation-altering ALS mutants impaired in this activity.\",\n      \"evidence\": \"Isogenic triple-knockout with single-paralog rescue, substrate degradation assays, E3 Co-IP, phase separation assays (preprint)\",\n      \"pmids\": [\"40631187\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Preprint, not peer-reviewed\", \"Mechanism distinguishing stabilization from degradation outcomes unclear\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"New metabolic substrates were identified, with UBQLN2 degrading ILVBL and ALDH3A2 and mutant-driven failure causing lipid metabolic dysfunction and neurodegeneration across multiple models.\",\n      \"evidence\": \"Multi-omics in iPSC neurons, cycloheximide chase, proteasome inhibition, rescue in neurons/organoids/mice\",\n      \"pmids\": [\"41912662\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct vs indirect recognition of these substrates not fully established\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Condensate partnerships with E3 ligases were extended, showing TRIM32 (and earlier TRIM9/TRIM26 toward mutant protein) form quality-control condensates capturing TDP-43 and ANXA11 via the STI1 domain, modulating aggregation.\",\n      \"evidence\": \"Co-IP, condensate/FRAP assays, E3 activity assays, human brain IHC (TRIM32 preprint); APEX2 proximity labeling and knockdown for TRIM9/TRIM26\",\n      \"pmids\": [\"41727138\", \"41582437\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"TRIM32 study is a preprint\", \"How E3 recruitment biases capture vs degradation undefined\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"UBQLN2 was implicated beyond ALS, with droplet liquid-to-solid transition catalyzing \\u03b1-synuclein fibril formation and colocalization with Lewy bodies, plus a small-molecule inhibitor of STI1-mediated self-association.\",\n      \"evidence\": \"In vitro LLPS/fibril assays, live imaging, PD brain IHC, inhibitor characterization (preprint)\",\n      \"pmids\": [\"bio_10.1101_2025.03.17.643602\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Preprint, not peer-reviewed\", \"Causal role of UBQLN2 in Parkinson's pathology not established in vivo\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How UBQLN2 toggles between promoting degradation and protecting substrates within condensates, and how this balance is set by ubiquitin chain linkage, E3 recruitment, and ALS mutations in vivo, remains the central open question.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model linking condensate state to substrate fate in cells\", \"Determinants selecting degradation vs stabilization E3 partners unknown\", \"In vivo measurement of condensate function in neurons lacking\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [3, 14]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [3, 9]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [20, 23]},\n      {\"term_id\": \"GO:0140313\", \"supporting_discovery_ids\": [20, 23]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [5, 11]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [3, 16]},\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [12, 13]},\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [1, 10]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [3, 9]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [11, 12]},\n      {\"term_id\": \"R-HSA-8953854\", \"supporting_discovery_ids\": [20]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [0, 26]}\n    ],\n    \"complexes\": [\n      \"UBQLN2-HSP70-HSP110 disaggregase machinery\",\n      \"MTM1-UBQLN2 complex\",\n      \"TRIM32-UBQLN2-p62 condensate\"\n    ],\n    \"partners\": [\n      \"HSPA1B\",\n      \"RPN10\",\n      \"UBXD8\",\n      \"ATP6v1g1\",\n      \"TIMM44\",\n      \"RTL8\",\n      \"PEG10\",\n      \"UBE3A\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}